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Summary
Background The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. 
Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This study 
assesses the current sex-specific HIV burden in 204 countries and territories and measures progress in the control of 
the epidemic.
Methods To estimate age-specific and sex-specific trends in 48 of 204 countries, we extended the Estimation and 
Projection Package Age-Sex Model to also implement the spectrum paediatric model. We used this model in cases 
where age and sex specific HIV-seroprevalence surveys and antenatal care-clinic sentinel surveillance data were 
available. For the remaining 156 of 204 locations, we developed a cohort-incidence bias adjustment to derive incidence 
as a function of cause-of-death data from vital registration systems. The incidence was input to a custom Spectrum 
model. To assess progress, we measured the percentage change in incident cases and deaths between 2010 and 2019 
(threshold >75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence 
ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0).
Findings In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1–38·9) people living with HIV 
worldwide. There were 0·84 males (95% UI 0·78–0·91) per female living with HIV in 2019, 0·99 male infections 
(0·91–1·10) for every female infection, and 1·02 male deaths (0·95–1·10) per female death. Global progress in 
incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in 
incident cases, 95% UI 19·58–35·43, and a 39·66% decrease in deaths, 36·49–42·36). Elsewhere, the incidence 
remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio 
was 0·05 (95% UI 0·05–0·06) and the global incidence-to-mortality ratio was 1·94 (1·76–2·12). No regions met 
suggested thresholds for progress.
Interpretation Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. 
The number of incident cases and deaths in males and females approached parity in 2019, although there remained 
more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on 
progress metrics.
Funding The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes 
of Health (NIH), and the National Institute on Aging of the NIH.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Millennium development goal 6 aimed to halt and reverse 
the spread of HIV/AIDS by 2015 and to achieve universal 
access to treatment by 2010.1 Although the world fell short 
of these goals, over the past two decades, HIV deaths 
and incident cases declined substantially.2 The sustainable 
development goals (SDGs) subsequently set a goal of 
ensuring healthy lives, which includes a promise by 
member states to end the AIDS epidemic as a public 
health threat by 2030.3 Assessing progress in the control 
of the HIV epidemic towards this aim, while remaining 
cognisant of sex-specific trends, is essential. Establishing 
this baseline before the indirect effects of the COVID-19 
pandemic have been fully realised is also crucial, because 
these effects might bear on the recalibration of future 
targets.4,5
Measurable targets relating to incidence and deaths 
have been proposed to assess progress in HIV, but they 
have not been synthesised to provide a comprehensive 
assessment of HIV burden. The original 90-90-90 targets 
were proposed in 2014,6 and set out that by 2020, 90% of 
people living with HIV will know their HIV status, 90% of 
those who are aware of their HIV-positive status will 
have initiated antiretroviral therapy (ART), and 90% of 
those on treatment will be virally suppressed. However, 
improve ments in these metrics might not necessarily 
reflect progress and data might be misreported;7 under-
reporting presents a problem for any modelling effort 
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that relies on treatment coverage to inform disease-
burden estimates. Several more measurable metrics were 
agreed upon at a meeting convened by UNAIDS in 2017.8 
These metrics include percentage reduction in HIV inci-
dence (75% reduction set as the threshold for 2010–20), 
percentage reduction in AIDS-related deaths (75% re-
duction set as the threshold for 2010–20), the ratio of the 
number of incident cases to prevalent cases (incidence-to-
prevalence ratio [IPR] set to a threshold of <0·03), and the 
ratio of number of incident cases to deaths among people 
living with HIV (incidence-to-mortality ratio [IMR] set to 
a threshold of <1·0; appendix, section 2.2, p 4). Together, 
these metrics can be used to provide a current 
epidemiological picture of HIV, but to our knowledge 
they have not been measured for all countries and 
territories.
In addition to assessing broad trends, understanding 
changes over time in the sex-specific burden of the HIV 
epidemic is crucial. Changes in the relative burden for 
males and females are evident, although research on 
this has been scarce.9–11 Although in sub-Saharan Africa 
women face a disproportionate burden,11 males in Europe 
and the USA faced a concentrated epidemic early on. 
In southeast Asia, concurrent epidemics among men 
who have sex with men (MSM), female sex workers, and 
people who inject drugs emerged.12 The HIV burden is 
also emerging in the super-regions of north Africa and 
the Middle East, and central Europe, eastern Europe, 
and central Asia, where incidence is rising among certain 
populations, such as MSM.13,14 Understanding the sex-
specific burden will provide better insight into current 
and future populations at risk.
Renewed focus on understanding differing HIV 
burden and trends among populations is necessary to 
achieving global targets for eliminating HIV as a public 
health threat by 2030. This study uses results from the 
Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD) 2019 to assess HIV burden in 204 countries 
and territories and across seven GBD super-regions 
from 1990 to 2019. The research aims to systematically 
assess trends in the HIV burden by sex and to measure 
progress towards SDGs. This manuscript was produced 




GBD is a systematic, scientific effort to quantify the 
comparative magnitude of health loss caused by diseases 
and injuries by age, sex, and location over time. 
Compared with our previous iteration,15 GBD 2019 
included nine add itional locations, for a total of 204 
countries and territories, and provided estimates from 
1990 to 2019. The study also included a new model, the 
Research in context
Evidence before this study
The Sustainable Development Goals aim to eliminate HIV and 
AIDS as a public health threat by 2030. HIV burden estimates 
are produced yearly by the Global Burden of Diseases, Injuries, 
and Risk Factors Study (GBD) in all countries, and UNAIDS in 
select countries, to help monitor progress. GBD 2017 assessed 
HIV and AIDS incidence, prevalence, and mortality, and 
coverage of antiretroviral therapy for 195 countries and 
territories. Although there are well documented declines in the 
generalised sub-Saharan African epidemic, case studies 
highlight acceleration of HIV incidence in key populations, 
including men who have sex with men, sex workers, and people 
who inject drugs. Against this changing epidemic, revised 
metrics and thresholds to measure progress related to 
incidence, prevalence, and deaths have been proposed by 
UNAIDS. These include percentage change in the number of 
incident cases and deaths since 2010 (>75% decrease), the 
incidence to prevalence ratio (<0·03), and the incidence to 
mortality ratio (<1·0).
Added value of this study
In the 2019 iteration of the GBD, we added nine new countries 
and territories, and updated HIV treatment and prevalence 
data. We also implemented a new model that allowed 
estimation of a transmission rate from age and sex specific HIV 
prevalence surveys in high-burden settings instead of relying 
on aggregate information. Additionally, we implemented a 
new method to account for bias in underlying antenatal care 
clinic-sentinel surveillance data that accounts for site location. 
We describe sex differences, and, for the first time, assess 
progress according to established metrics. Incident cases and 
deaths in males and females approached parity in 2019, 
reflecting declines in the female-dominated epidemic in 
sub-Saharan Africa. Despite this progress, countries and 
territories were not on track to meet thresholds related to 
reductions in incidence, prevalence, incidence-to-mortality 
ratio (IMR), or incidence-to-prevalence ratio (IPR).
Implications of all the available evidence
Sub-Saharan Africa continues to have the greatest burden of 
HIV, although our findings corroborate increasing concern 
about trends in HIV incidence outside this region. Although 
declines in incident cases and deaths in sub-Saharan Africa 
drove sex parity globally, challenges in engaging at-risk groups, 
including young women and key populations, are known in 
sub-Saharan Africa and other regions. These communities could 
be of increasing relative importance in curbing HIV in the 
future. Progress was inconsistent across regions and did not 
meet proposed thresholds. Decomposing the IMR and IPR in 
future analyses will allow policy makers to better understand 
the patterns in progress and design more targeted and 
hopefully increasingly-successful programmes.
See Online for appendix
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estimation and projection package age-sex model (EPP-
ASM). The conceptual and analytical framework for 
GBD 2019, its hierarchy of causes, and detailed methods 
have been published elsewhere.16–18 Here we describe the 
specific methods used in GBD 2019 for analysing the 
burden of HIV (appendix, section 2.1, p 4). The study is 
compliant with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (also known as 
GATHER);19 data and code for GBD 2019 HIV estimation 
process are available online. As part of GBD, seven 
super-regions were defined as follows: high income; 
sub-Saharan Africa; southeast Asia, east Asia, and 
Oceania; south Asia; north Africa and the Middle East; 
Latin America and the Caribbean; and central Europe, 
eastern Europe, and central Asia (appendix, section 2.3, 
figure S2, p 6).
Modelling strategy
We grouped countries and territories on the basis of 
availability of different types of data to use unique 
modelling strategies that capitalise on the best available 
data in each country. Group 1 included countries and 
territories with HIV-prevalence data from antenatal care 
clinics or representative population-based seroprevalence 
surveys (ie, 48 countries in total, including several in sub-
Saharan Africa and in the Dominican Republic, Haiti, 
India, Papua New Guinea, and Sudan). Group 2 included 
the remaining 156 countries, which generally had data 
on HIV deaths, except for 33 countries with no data on 
HIV deaths. The groups were further divided on the 
basis of peak prevalence with or without registration-data 
completeness (appendix, section 2.3, figure S1, p 6).
To estimate sex-specific HIV burden and trends for 
countries and territories in group 1, we improved the 
published version of EPP-ASM.20 To augment this model, 
we first developed and included an offset term applied to 
antenatal care data that accounts for site location. This 
term captures the difference between the prevalence in a 
given antenatal care-site year and the national prevalence 
in that year (appendix, section 2.5.2, p 10). Second, to 
obtain results for all ages, we developed and implemented 
a paediatric model (for those aged <15 years) within 
EPP-ASM; the published version only provided results 
for adults. This model was based on the paediatric 
component originally in Spectrum,21 the model used by 
many national programmes and UNAIDS to estimate the 
annual status of the HIV epidemic, incorporating child-
treatment inputs and demographics. Finally, we derived 
priors for the incidence-rate ratios that were used to split 
larger age groups into smaller ones within the population 
projection. Simple linear models of observed survey 
prevalence against year informed our priors for the 
change of ratios over time and intercepts (appendix, 
section 2.5.2, p 11).
India was a modelling exception to other group 1 
countries because we sought to use available data from 
antenatal care sentinel surveillance and from the 
sample registration system (SRS) on HIV deaths. 
We used an in-house version of the original estimation 
and projection package22 to estimate incidence and 
prevalence on the basis of data on antenatal care. We 
then used data on SRS deaths to inform age and sex 
patterns in incidence and deaths via cohort incidence 
bias adjustment (CIBA). Spectrum was used for final 
estimates.
For all countries in group 2, we developed CIBA with 
a modified version of Spectrum to estimate age and sex-
specific HIV burden and trends. CIBA is a demographic 
cohort model that addresses the general scarcity of 
reliable data on incidence that could provide a gold-
standard incidence to use as input for the Spectrum 
model. CIBA instead aims to derive a plausible inci-
dence from more-reliable data on HIV deaths. We 
selected the incidence to input from estimates available 
as part of public-use files or the incidence estimated as 
part of a past GBD cycle that best minimised the 
ultimate bias between data from Spectrum deaths 
and reported deaths. To create an adjustment factor, 
we determined the ratio of Spectrum deaths to vital 
statistics deaths for each year. Age and sex specific 
incidence cohorts were defined by year of infection. 
The cohort that would have produced those deaths was 
scaled by this factor using the cohort-survival estimates 
derived from Spectrum (appendix, section 2.5.4, p 12). 
We provide a flowchart and full description of models, 
improvements, and additional adjustments (appendix, 
section 2.5, figure S3, p 9).
Input data
Country-specific inputs that are common across the 
modelling strategies included data on demographic 
estimates and intervention coverage reported to UNAIDS, 
such as ART and prevention of mother-to-child trans-
mission. Rates of disease progression and HIV-free 
mortality (ie, the expected background mortality 
not caused by HIV), required for both models were also 
inputs for all countries and territories.18 Model-specific 
inputs for countries and territories in group 1 for which 
EPP-ASM was used included population-representative 
HIV sero prevalence surveys and antenatal care data that 
were also adjusted to be population representative. For 
countries and territories in group 2, we used adjusted 
vital registration data (appendix, section 2.4, p 7).
Estimating uncertainty
All the models were run 1000 times to create 1000 draws 
from which 95% uncertainty intervals (UIs) were 
derived, with the 2·5th and 97·5th percentile draws as 
the upper and lower bounds. On-ART and off-ART 
mortality were modelled separately. To propagate 
uncertainty, one draw was randomly selected each time 
EPP-ASM and Spectrum were run. We drew treatment 
inputs from a uniform distribution on each draw to 
ensure adequate uncertainty was captured.
For more on the data and code 
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Assessing epidemic trends and progress
Sex-specific burden was assessed using the ratio 
of male-to-female incident cases, deaths, and people 
with HIV. Progress was measured using the UNAIDS 
metrics.8 We derived the percentage change in number 
of incident cases and deaths using case counts in 2019 
versus 2010.
Y is either the total number of incident cases or the total 
number of deaths and c is the location. The IPR and 
IMR for 2010 and 2019 were also derived. IPR was 
measured using incident cases for all ages and both 
sexes combined over prevalent cases for all ages and 
both sexes combined. The IMR for 2010 and 2019 were 
measured as the number of incident cases over the total 
number of deaths from any cause among people living 
with HIV. Uncertainty for each measure was similarly 
derived using draw-level results from the modelling 
processes.Figure 1: Global HIV burden 1990–2019
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Figure 2: Male-to-female sex ratios for 204 countries and territories in 2019
Incident cases (A). Deaths (B) Countries and territories with fewer than 100 incident cases or deaths in 2019 were excluded from this calculation because of small 
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Ethical approval
The University of Washington Institutional Review 
Board Committee approved GBD 2019 (approval number 
STUDY00009060). The study is approved until Dec 2, 2021.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
36·8 million (95% UI 35·1–38·9) people were living 
with HIV in 2019. Of these, 16·8 million (15·6–18·4) 
were male, and 20·1 million (19·3–20·9) were female. 
Over the 1990–2019 study period, the number of 
incident cases peaked globally in 1997 at 3·3 million 
(95% UI 2·8–4·0), whereas deaths peaked later, in 
2004, at 1·8 million (1·5–2·2; figure 1). These estimates 
varied greatly by country and territory (appendix, 
section 2.7, figures S4A–C, pp 16–17), although sub-
Saharan Africa had the highest number of incident 
cases, deaths, and people living with HIV in every study 
year. This region had 83·3% (95% UI 77·8–87·5) of the 
global number of incident cases, 78·5% (73·4–83·5) of 
the global number of deaths, and 74·1% (67·1–80·0) of 
the global number of people living with HIV in 1990. 
These numbers declined to 64·8% (58·6–70·4), 74·0% 
(70·7–77·2), and 70·7% (66·8–73·8), respectively, by 
2019 (appendix, section 2.7, figure S5, p 17).
As of 2019, prevalent cases were continuing to 
rise globally, while incident cases and deaths were 
declining. Between 1990 and 1999, the global number of 
people living with HIV increased by an annual mean 
of 13·7% (95% UI 12·6–14·8) per year compared with 
2·4% (2·0–2·7) per year in 2010–19. For incident cases, 
the fastest decline globally occurred in the decade 
between 2000 and 2009 (annualised rate of decline 2·7%, 
95% UI 2·0–3·4), which came after the fastest decade of 
acceleration, between 1990 and 1999 (annualised rate of 
increase 5·1%, 3·9–6·5). By 2010–19, the number of 
incident cases also declined at a slower annual rate than 
deaths (mean decrease per year of 1·8%, 0·8–2·7, 
vs annual decrease of 5·2%, 4·5–5·7; figure 2).
The global numbers of male and female HIV incident 
cases and deaths approached parity in 2019, whereas 
prevalent cases remained disparate. In 2019, there were 
0·99 new infections (95% UI 0·91–1·10) among males 
for every new infection among females, 1·02 HIV 
deaths (0·95–1·10) among males per HIV death 
among females (figure 3), and 0·84 males with HIV 
(0·78–0·91) per female with HIV (appendix, section 2.7, 
figure S5, p 17).
In 2019, sex differences varied considerably by super-
region (appendix, section 2.7, figure S5, p 17). Ratios 
were the most skewed towards females in sub-Saharan 
Africa, at 0·68 new infections (95% UI 0·63–0·75) 
among males per infection among females and 
0·84 deaths (95% UI 0·77–0·92) among males per death 
among females. High-income super-regions had the 
highest ratios of new infections among males per female 
infection (2·42, 2·11–2·76) and deaths among males to 
deaths among females (2·83, 2·79–2·87).
By contrast to deaths and incident cases, the global 
number of males with HIV remained lower than the 
number of females with HIV in 2019. The global number 
of females with HIV increased faster than that of males 
with HIV between 1990 and 1999, at 14·7% (95% UI 
13·4–16·1) per year versus 12·5% (11·5–13·8) per year. 
Between 2010 and 2019, however, females with HIV 
increased by a mean of 2·4% (2·0–2·8) per year, which 
was similar to the increase in males with HIV (increase 
per year of 2·3%, 2·0–2·7). At the super-region level, 
patterns in prevalent-case sex ratios were similar to those 
of incident cases and deaths (appendix, section 2.7, 
figures S6–8, pp 18–19).
The global number of HIV incident cases declined 
by 16·10% (95% UI –22·31 to –8·07) between 
2010 and 2019, a change from 2·4 million (95% UI 
2·2 to 2·7) new infections in 2010 to 2·0 million 
Figure 3: Change in HIV burden by GBD super-region for both sexes combined, by decade, from 1990 to 2019
(A) Annualised rate of change: derived as the mean yearly percentage change averaged over the given time period. 
(B) Total percentage change: the labelled numbers are the global percentage change in each measure over the 
given time period. Each bar shows the proportion and direction of change attributable to each super-region. 
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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(1·8 to 2·3) new infections in 2019. Between 
2010 and 2019, the number of HIV deaths declined 
by 36·75% (–39·95 to –32·64), a change from 1·4 million 
deaths (1·2 to 1·6) in 2010 to 864 000 deaths 
(786 000 to 996 000) in 2019. Neither incidence nor 
deaths approached the desired 75% reduction target.
Between 2010 and 2019, the decline in incident 
cases was driven by trends in sub-Saharan Africa, where 
incident cases fell by 28·50% (95% UI 19·58 to 35·43). 
On the other end of the spectrum was central Europe, 
eastern Europe, and central Asia, where incident cases 
increased by 107·45% (72·66 to 139·13) from 2010 to 
2019, and the high-income super-region, where incident 
cases increased by 35·65% (3·38 to 55·91; table 1). We 
present country-level findings in a supplementary table 
(appendix, section 2.7, table S2, p 31).
Almost all super-regions contributed to the global 
decrease in deaths between 2010 and 2019, or showed 
IMR, 2010 IMR, 2019 IPR, 2010 IPR, 2019 Percentage change in deaths, 
2010–19
Percentage change in 
incidence, 2010–19
Global 1·59 (1·53 to 1·65) 1·94 (1·76 to 2·12) 0·08 (0·07 to 0·09) 0·05 (0·05 to 0·06) –36·75% (–39·95 to –32·64) –16·10% (–22·31 to –8·07)
Central Europe, eastern 
Europe, and central Asia
2·82 (2·41 to 3·29) 4·76 (3·96 to 5·78) 0·15 (0·12 to 0·19) 0·11 (0·09 to 0·12) 6·85% (5·10 to 8·57) 107·45% (72·66 to 139·13)
High income 3·29 (2·45 to 4·17) 3·91 (2·65 to 4·98) 0·04 (0·03 to 0·05) 0·04 (0·03 to 0·05) –20·26% (–21·02 to –19·55) 35·65% (3·38 to 55·91)
Latin America and Caribbean 2·25 (2·07 to 2·49) 2·61 (2·31 to 3·04) 0·09 (0·08 to 0·11) 0·07 (0·06 to 0·08)  –12·61% (–18·36 to –6·92) 11·75% (–1·82 to 23·47)
North Africa and Middle East 1·97 (1·27 to 3·18) 2·37 (1·48 to 4·19) 0·13 (0·10 to 0·17) 0·12 (0·08 to 0·17) 24·06% (–14·03 to 81·80) 52·40% (–2·87 to 172·14)
South Asia 0·73 (0·54 to 0·95) 1·40 (0·90 to 1·94) 0·06 (0·04 to 0·08) 0·05 (0·03 to 0·07)  –60·25% (–66·18 to –44·03)  –13·77% (–40·18 to 33·70)
Southeast Asia, east Asia, and 
Oceania
1·87 (1·62 to 2·23) 1·83 (1·6 to 2·19) 0·08 (0·07 to 0·01) 0·07 (0·06 to 0·08) 5·96% (–8·69 to 18·17) 4·91% (–7·40 to 16·76)
Sub-Saharan Africa 1·51 (1·46 to 1·57) 1·63 (1·44 to 1·82) 0·08 (0·07 to 0·01) 0·05 (0·04 to 0·06)  –39·73% (–42·36 to –36·49) –28·50% (–35·43 to –19·58)
Data in parentheses are 95% uncertainty intervals. The IPR threshold was set as less than 0·03, and the threshold for the IMR was set to less than 1·0. The incidence and deaths threshold was at least a 
75% reduction since 2010.8 GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. IMR=incidence-to-mortality ratio. IPR=incidence-to-prevalence ratio.
Table 1: UNAIDS progress metrics by GBD super-region in 2010 and 2019
1990 1999 2009 2019





































































































































































































(Table 2 continues on next page)
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minimal change. The largest declines were again in 
south Asia and sub-Saharan Africa. Deaths in south 
Asia declined by 60·25% (44·03 to 66·18) from 2010 to 
2019, whereas deaths in sub-Saharan Africa declined 
by 39·73% (36·49 to 42·36). Two super-regions, 
the high-income super-region and Latin America and 
the Caribbean, saw smaller declines, whereas the other 
three super-regions had modest increases (appendix, 
section 2.7, table S1, p 19, for country and super-region 
results). We present the number of deaths in each 
super-region for each decade (table 2).
At the national level, 40 (87%) of 46 countries in 
sub-Saharan Africa saw declines in deaths. The decline 
was greatest in Burundi (percentage change in deaths for 
2010–19 was –72·77, 95% UI –77·50 to –65·43). In central 
Europe, eastern Europe, and central Asia, nine of 
29 countries had more HIV deaths in 2019 than 2010. 
Only Georgia had an increase greater than 100%, 
although this was driven by low absolute numbers of 
deaths, with an increase of 174·52% (156·54–195·18), 
from eight deaths (8–9) in 2010 to 23 deaths (22–24) 
in 2019. In north Africa and the Middle East, 14 (67%) of 
21 countries and territories had increases in mean 
deaths. Most notably in this region, in Iran, deaths 
increased by 108·04% (52·23–189·15), from 565 deaths 
(486–646) in 2010 to 1180 deaths (852–1710) in 2019, 
whereas Turkey saw a 101·95% (60·34–144·22) increase, 
from 112 deaths (91–140) in 2010 to 226 deaths (182–265) 
in 2019. In southeast Asia, east Asia, and Oceania, 
deaths increased faster than incident cases (table 2), and 
although 12 countries showed declines over the decade, 
the remaining 22 countries had increases in deaths 
(appendix, section 2.7, table S1, p 19).
The global HIV IPR (number of new infections per 
person with HIV) was 0·05 (95% UI 0·05–0·06) in 2019, 
compared with 0·08 (0·07–0·09) in 2010, thus not 
reaching the proposed threshold of 0·03. The IMR 
(number of new infections per death among people with 
HIV) was 1·94 (1·76–2·12) in 2019 compared with 1·59 
(1·53–1·65) in 2010, also not reaching the threshold of 
1·0 (table 1).
Progress towards achieving these UNAIDS bench-
marks was inconsistent between the different super-
regions. In 2010, the high-income super-region had 
the highest IMR, at 3·29 (2·45–4·17), whereas central 
Europe, eastern Europe, and central Asia had the highest 
1990 1999 2009 2019
Males Females Males Females Males Females Males Females
(Continued from previous page)




































































































































































































Data in parentheses are 95% uncertainty intervals. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
Table 2: Number of deaths, incident cases, and prevalent cases (thousands) globally and by GBD super-region, for both sexes combined, in 1990, 2000, 2010, and 2019 
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in 2019 (4·76, 3·96–5·78). The lowest IMR in both 2010 
and 2019 occurred in south Asia (0·73, 0·54–0·95, in 
2010 and 1·40, 0·90–1·94, in 2019; table 1). By contrast 
to its high IMR, the high-income super-region had the 
lowest IPR in 2010 and 2019 (both years 0·04, 0·03–0·05), 
whereas north Africa and the Middle East (0·12, 
Deaths decreased, incidence decreased Deaths increased, incidence decreased
Deaths increased, incidence increased Deaths decreased, incidence increased
1 2 3 4 1 2 3 4
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prevalence ratios for 
204 countries and territories 
in 2010 versus 2019, 
and direction of change from 
2010 to 2019
The blue dotted lines 
represent UNAIDS thresholds 
(<1·0 for incidence-to 
mortality ratio and <0·03 for 
incidence-to-prevalence ratio). 
Points to the left of the vertical 
line met the threshold in 2019, 
whereas points below the 
horizontal line met the 
threshold in 2010. Countries 
and territories are sorted into 
a directional change matrix for 
deaths and incidence on the 
basis of changes between 
2010 and 2019.
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0·08–0·17) and central Europe, eastern Europe, and 
central Asia (0·11, 0·09–0·12) had the highest IPRs in 
2019 (table 1).
Changes in IMRs and IPRs were driven by different 
trends in the underlying measures within different coun-
tries (figure 4). The highest IMRs in 2019 were found 
primarily in locations where deaths decreased and 
incident cases increased since 2010 (nine of the ten coun-
tries and territories with the highest IMRs), whereas the 
lowest IMRs were in locations where both deaths and 
incident cases decreased (nine out of the ten with the 
lowest IMRs; appendix, section 2.7, table S5, p 60). Seven 
of the ten locations with the lowest IPRs in 2019 had 
both decreasing deaths and incident cases, whereas the 
remaining three locations had decreasing deaths and 
increasing incident cases. The top ten locations with the 
highest IPRs had increases in both deaths and incident 
cases between 2010 and 2019 (appendix, section 2.7, 
table S4, p 51).
Discussion
Globally, the number of HIV incident cases and deaths 
decreased over the past two decades, while the gap 
between incident cases and deaths in males and females 
shrank. Because of the high prevalence of HIV among 
females in sub-Saharan Africa, the number of people 
living with HIV remained higher in females than in 
males globally. The decreases in incident cases and deaths 
did not achieve a 75% decrease between 2010 and 2019; 
nevertheless, the IPR decreased between 2010 and 2019, 
approaching the UNAIDS bench mark of 0·03.8 The IMR, 
however, increased in nearly all super-regions over the 
same period, and no super-region approached the 
benchmark of 1·0. At the same time, the changes to IMR 
and IPR reflected different underlying trends in incidence 
and mortality. Our findings point towards an evolving 
epidemic and the need to consider alternative metrics to 
IMR and IPR for a complete picture of the epidemic to 
inform policy.
Large declines in incidence and deaths in sub-Saharan 
Africa drove growing global sex parity in these two 
measures. Females have a disproportionate HIV burden 
in sub-Saharan Africa because of vulnerabilities ranging 
from younger sexual debut, sexual transactions with 
older men, and sexual violence,23 to biology that makes it 
easier for men to transmit to women, particularly when 
women are young.24 Progress in sub-Saharan Africa 
coincided with global health funding available for HIV in 
the 2000s,25 ART scale-up,26 HIV/AIDS programmes that 
improved health-service delivery and infrastructure,27 
and prevention efforts.28,29 Despite the progress, sub-
Saharan Africa still shares an overwhelming burden 
of HIV. The region does not meet the thresholds 
under study, and global investments have plateaued.25 
More granular work has also revealed heterogeneous 
patterns and changing HIV demographics within 
countries30,31 and the potential for subnational variation,32 
and high lights the ongoing dual burden with tuberculosis 
(unpublished). Elsewhere, males have a higher HIV 
burden, including in central Europe, eastern Europe, and 
central Asia and the high-income super-region, where 
the number of incident cases increased and the IMRs 
were highest in 2019. Injectable drug use has driven 
transmission through needles in eastern Europe and 
central Asia.33
The ongoing epidemic in Africa, incidence growth, and 
failure to meet progress targets corroborate calls for the 
increasing importance of surveillance and engagement 
strategies targeting at-risk groups, including key popu-
lations. Although we did not seek to model key 
populations specifically, our finding, for instance, of sex 
parity in HIV burden in north Africa and the Middle East 
could be masking a hidden male epidemic thought 
to exist among MSM related to missing data and 
low testing.14 In sub-Saharan Africa, prevention efforts 
have not had great success in reaching, in particular, 
adolescents,34 and key populations still face higher HIV 
risk and prevalence,35 like elsewhere.12,36–38 Pre-exposure 
prophylaxis (PrEP) was associated with impressive 
incidence reductions, for example in MSM in Australia,39 
but PrEP often does not reach the entirety of the 
population it could target.40,41 Reducing the stigma and 
marginalisation that lower engagement in HIV pre-
vention and treatment are thus essential to achieve global 
targets.42,43 Historically, affected communities initiated 
or propagated behavioural change that drove down 
HIV. The Sonagachi HIV/AIDS intervention in India, 
for instance, demonstrated the key role of brothels in 
its success among female sex workers.44 Targeted govern-
ment investment and programmes have also successfully 
supported reducing HIV infections in key populations.45 
For example, the Thai government almost managed to 
eliminate mother-to-child transmission through exten-
sive monitoring, prevention, and treatment policy.46 
Failing to identify and engage at-risk populations inhibits 
the overall potential for progress.
To assess progress, metrics apart from IMR and IPR 
that do not rely primarily on changes to people with 
HIV might become increasingly relevant. The number 
of people with HIV can increase because of increasing 
incident cases or decreasing number of deaths as people 
live longer. Advances in and access to treatment have 
meant that life expectancies of people with HIV have 
approached those without HIV.47 An IMR of greater 
than 1·0, indicating a growing number of people with 
HIV, could reflect progress as early deaths decline. 
Galvani and colleagues48 also underscored scenarios in 
sub-Saharan Africa in which negative or positive 
changes could result in non-intuitive IMRs and IPRs. 
Relying on the size of the population of people with 
HIV could thus mask needed policy efforts that address 
the new challenges opened by longer lifespans for 
people with HIV.49 The growing number of people with 
HIV in the long term also underscores the importance 
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of reducing the number of incident cases to constrain 
long-term ART costs for decades to come.50 These 
factors are reflected in the US President’s Emergency 
Plan for AIDS Relief (PEPFAR), which suggests that 
IMR only be used in settings with high ART coverage.51 
As such, further decomposing changes in prevalence 
and the numerators and denominators of IMR and IPR 
becomes essential, rendering the metrics less useful in 
isolation.
The COVID-19 pandemic has the potential to 
complicate progress in controlling HIV epidemics, 
although research on this issue is scarce. People living 
with HIV do not seem to have higher susceptibility to 
severe COVID-19, although vulnerable social status in 
this population might put them at higher risk than the 
general population.52 There are also potential challenges 
related to treatment services, including timely access 
to care, continuing on treatment, and HIV testing.53 
One survey in China in February, 2020, found that about 
64% of people living with HIV in Hubei province 
reported difficulty accessing antiretrovirals because of 
barriers.54 In Kenya, there were concerning trends in 
turnaround times for HIV testing, numbers of tests, and 
clinical restructuring for COVID-19 mitigation.55 There 
are, however, important efforts under way to mitigate 
these disruptions. In China, the Chinese National Centre 
for AIDS/STD Control and Prevention has worked to 
ensure people with HIV can collect medications.56 In 
Kenya, the Ministry of Health allowed early refills for an 
extra 3 month supply of antiretrovirals.57 Although these 
are just case studies, broader efforts through WHO, 
PEPFAR, UNAIDS, and the Global Network of People 
Living with HIV are working to this end.58–61
Comparing GBD HIV estimates with those published 
by UNAIDS is useful. For the year 2019, we estimated 
36·8 million (95% UI 35·1–38·9) people with HIV, 
1·99 million (1·76–2·26) incident cases, and 864 000 
(786 000–996 000) deaths, compared with the UNAIDS 
2020 published estimates of 38·0 million (31·6–44·5) 
people with HIV, 1·7 million (1·2–2·2) incident cases, 
and 690 000 (500 000–970 000) deaths globally in 2019.62 
Although the GBD estimate of people with HIV is 
the most similar, higher incidence and deaths are a 
reflection of several important differences in GBD 
methods compared with UNAIDS: we did an independ-
ent systematic review and synthesis model for on-
treatment mortality and progression parameters that 
were important inputs in both Spectrum and EPP-ASM 
(appendix, section 2.5, p 9); we incorporated the CIBA 
process, which involves estimating incidence with 
mortality data; we used GBD population, fertility, 
births, and migra tion estimates in the population 
projection; and the modelling strategy across groups of 
countries for UNAIDS is more heterogeneous, with for 
example the Asian Epidemic Model in southeast Asia. 
Further, GBD provides two important advantages 
unavailable from UNAIDS, which include internally 
consistent estimates with other causes of death and 
similar estimates across diseases.
This study has several limitations. The results of 
the cohort-incidence bias adjustment approach to in-
corpor ating vital registration data are sensitive to our 
initial incidence input to the first stage of Spectrum. 
Although we aimed to mitigate this problem by choosing 
the most plausible incidence option that yields deaths 
closest to more trustworthy vital registration data, there 
is a general scarcity of reliable data on incidence that 
could provide a gold-standard incidence input. Future 
work establishing the most likely incidence in a 
statistical framework could improve the selection of the 
incidence input relative to vital registration data and 
thus improve final burden estimates. The results are 
also affected by the limitations of the best data sources of 
countries and territories. Although GBD aims to make 
use of the best-available and most-recent data in different 
countries and territories, such data are prone to different 
biases related to sampling and modelling. Sex 
differences, for example, can be driven by modelling 
assumptions for which data are scarce or the dominant 
data source (case reports, vital statistics, or prevalence 
surveys) does not capture certain groups. We expect our 
incidence estimates might be too low in cases in which 
official data exclude certain population segments. 
Related to this issue, because of the scarcity of 
comprehensive data regarding HIV prevalence in gender 
non-conforming, intersex, and transgender individuals, 
a male-female binary was used in this research. Despite 
not having this data, HIV often disproportionately 
affects these populations, and this work is limited by the 
inability to provide estimates at a finer granularity of sex 
and gender identity. In countries and territories without 
data, our estimates rely on the assumption that regional 
means provide a good proxy for required treatment and 
other model inputs.16 Because countries and territories 
without data tend to have smaller HIV epidemics, we 
believe this assumption has limited consequences for 
regional or global estimates. Still, we might not be 
accurately capturing the epidemic in these locations if 
they are outliers in their region.
HIV incident cases and deaths decreased over the past 
two decades, while the number of people living with HIV 
continued to increase through 2019. The difference in 
the number of incident cases and deaths in males and 
females shrank whereas the number of females living 
with HIV remained higher than in males living with HIV 
in 2019. The largest decrease in incidence and deaths was 
in sub-Saharan Africa, where females also have a higher 
burden of HIV. Incidence increased the fastest in regions 
where HIV incidence concentrates in key populations, 
central Europe, eastern Europe, and central Asia, and the 
high-income super-region.
Although global trends in IPRs are decreasing, a sign 
of progress, IMRs were higher in more regions in 2019 
than 2010, and did not meet benchmarks set by the 
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UNAIDS consensus. However, as the number of people 
with HIV expands because of declining deaths rather 
than increasing incidence, IMRs and IPRs might not be 
sufficient for measuring HIV progress. Estimating HIV 
burden and trends in different populations remains 
crucially important to provide policy makers with 
information to design effective control measures.
Contributors
Author contributions are listed in the appendix (pp 61–64). The 
corresponding author had full access to the data in the study and had 
final responsibility for the decision to submit for publication.
GBD 2019 HIV Collaborators
Deepa Jahagirdar, Magdalene K Walters, Amanda Novotney, 
Edmond D Brewer, Tahvi D Frank, Austin Carter, Molly H Biehl, 
Hedayat Abbastabar, E S Abhilash, Eman Abu-Gharbieh, 
Laith Jamal Abu-Raddad, Victor Adekanmbi, Daniel Adedayo Adeyinka, 
Qorinah Estiningtyas Sakilah Adnani, Saira Afzal, 
Soodabeh Aghababaei, Bright Opoku Ahinkorah, Sajjad Ahmad, 
Keivan Ahmadi, Sepideh Ahmadi, Ehsan Ahmadpour, 
Muktar Beshir Ahmed, Tarik Ahmed Rashid, Yusra Ahmed Salih, 
Addis Aklilu, Tayyaba Akram, Chisom Joyqueenet Akunna, 
Hanadi Al Hamad, Fares Alahdab, Fahad Mashhour Alanezi, 
Ekaterina A Aleksandrova, Kefyalew Addis Alene, Liaqat Ali, 
Vahid Alipour, Sami Almustanyir, Nelson Alvis-Guzman, 
Edward Kwabena Ameyaw, Hubert Amu, Catalina Liliana Andrei, 
Tudorel Andrei, Davood Anvari, Jalal Arabloo, Olatunde Aremu, 
Judie Arulappan, Desta Debalkie Atnafu, 
Beatriz Paulina Ayala Quintanilla, Muluken Altaye Ayza, Samad Azari, 
Darshan B B, Maciej Banach, Till Winfried Bärnighausen, 
Fabio Barra, Amadou Barrow, Sanjay Basu, Shahrzad Bazargan-Hejazi, 
Habtamu Gebrehana Belay, Tezera Moshago Berheto, 
Woldesellassie Mequanint Bezabhe, Yihienew Mequanint Bezabih, 
Akshaya Srikanth Bhagavathula, Nikha Bhardwaj, Pankaj Bhardwaj, 
Krittika Bhattacharyya, Sadia Bibi, Ali Bijani, Catherine Bisignano, 
Obasanjo Afolabi Bolarinwa, Archith Boloor, Azizbek A Boltaev, 
Nikolay Ivanovich Briko, Danilo Buonsenso, Katrin Burkart, 
Zahid A Butt, Chao Cao, Jaykaran Charan, Souranshu Chatterjee, 
Soosanna Kumary Chattu, Vijay Kumar Chattu, 
Sonali Gajanan Choudhari, Dinh-Toi Chu, Rosa A S Couto, 
Richard G Cowden, Berihun Assefa Dachew, Omid Dadras, 
Amare Belachew Dagnew, Saad M A Dahlawi, Xiaochen Dai, 
Lalit Dandona, Rakhi Dandona, José das Neves, Louisa Degenhardt, 
Feleke Mekonnen Demeke, Abebaw Alemayehu Desta, Keshab Deuba, 
Deepak Dhamnetiya, Govinda Prasad Dhungana, Mostafa Dianatinasab, 
Daniel Diaz, Shirin Djalalinia, Linh Phuong Doan, Fariba Dorostkar, 
Hisham Atan Edinur, Andem Effiong, Sahar Eftekharzadeh, 
Maysaa El Sayed Zaki, Rajesh Elayedath, Muhammed Elhadi, 
Shaimaa I El-Jaafary, Ziad El-Khatib, Aisha Elsharkawy, 
Aklilu Endalamaw, Aman Yesuf Endries, Sharareh Eskandarieh, 
Ifeanyi Jude Ezeonwumelu, Sayeh Ezzikouri, Mohammad Farahmand, 
Emerito Jose A Faraon, Abidemi Omolara Fasanmi, Simone Ferrero, 
Lorenzo Ferro Desideri, Irina Filip, Florian Fischer, 
Morenike Oluwatoyin Folayan, Masoud Foroutan, Takeshi Fukumoto, 
Mohamed M Gad, Muktar A Gadanya, Abhay Motiramji Gaidhane, 
Tushar Garg, Reta Tsegaye Gayesa, Eyob Alemayehu Gebreyohannes, 
Hailay Abrha Gesesew, Abera Getachew Obsa, Keyghobad Ghadiri, 
Ahmad Ghashghaee, Syed Amir Gilani, Themba G Ginindza, 
Ionela-Roxana Glăvan, Ekaterina Vladimirovna Glushkova, 
Mahaveer Golechha, Harish Chander Gugnani, Bhawna Gupta, 
Sapna Gupta, Veer Bala Gupta, Vivek Kumar Gupta, Samer Hamidi, 
Senad Handanagic, Shafiul Haque, Harapan Harapan, Arief Hargono, 
Ahmed I Hasaballah, Abdiwahab Hashi, Shoaib Hassan, 
Soheil Hassanipour, Khezar Hayat, Ileana Heredia-Pi, Kamal Hezam, 
Ramesh Holla, Praveen Hoogar, Mohammad Enamul Hoque, 
Mostafa Hosseini, Mehdi Hosseinzadeh, Mohamed Hsairi, 
Rabia Hussain, Segun Emmanuel Ibitoye, Bulat Idrisov, Kevin S Ikuta, 
Olayinka Stephen Ilesanmi, Irena M Ilic, Milena D Ilic, 
Seyed Sina Naghibi Irvani, M Mofizul Islam, Nahlah Elkudssiah Ismail, 
Ramaiah Itumalla, Ihoghosa Osamuyi Iyamu, Roxana Jabbarinejad, 
Vardhmaan Jain, Ranil Jayawardena, Ravi Prakash Jha, Nitin Joseph, 
Ali Kabir, Zubair Kabir, Rohollah Kalhor, Feroze Kaliyadan, 
Ashwin Kamath, Tanuj Kanchan, Himal Kandel, Getinet Kassahun, 
Patrick DMC Katoto, Gbenga A Kayode, Ermiyas Mulu Kebede, 
Hafte Kahsay Kebede, Himanshu Khajuria, Nauman Khalid, 
Ejaz Ahmad Khan, Gulfaraz Khan, Khaled Khatab, Min Seo Kim, 
Yun Jin Kim, Adnan Kisa, Sezer Kisa, Sonali Kochhar, 
Vladimir Andreevich Korshunov, Parvaiz A Koul, 
Sindhura Lakshmi Koulmane Laxminarayana, Ai Koyanagi, 
Kewal Krishan, Barthelemy Kuate Defo, G Anil Kumar, Manasi Kumar, 
Nithin Kumar, Alexander Kwarteng, Dharmesh Kumar Lal, 
Iván Landires, Savita Lasrado, Zohra S Lassi, Jeffrey V Lazarus, 
Jane Jean-Hee Lee, Yeong Yeh Lee, Kate E LeGrand, Christine Lin, 
Xuefeng Liu, Emilie R Maddison, Hassan Magdy Abd El Razek, 
Phetole Walter Mahasha, Azeem Majeed, Alaa Makki, 
Ahmad Azam Malik, Wondimu Ayele Manamo, 
Mohammad Ali Mansournia, Francisco Rogerlândio Martins-Melo, 
Seyedeh Zahra Masoumi, Ziad A Memish, Ritesh G Menezes, 
Endalkachew Worku Mengesha, Hayimro Edemealem Merie, 
Amanual Getnet Mersha, Tomislav Mestrovic, Peter Meylakhs, 
Nour Mheidly, Ted R Miller, Andreea Mirica, Babak Moazen, 
Yousef Mohammad, Mokhtar Mohammadi, Arif Mohammed, 
Salahuddin Mohammed, Shafiu Mohammed, Modhurima Moitra, 
Ali H Mokdad, Mariam Molokhia, Mohammad Ali Moni, 
Ghobad Moradi, Yousef Moradi, Christine Mpundu-Kaambwa, 
Sumaira Mubarik, Sandra B Munro, Lillian Mwanri, Jean B Nachega, 
Ahamarshan Jayaraman Nagarajan, Aparna Ichalangod Narayana, 
Muhammad Naveed, Biswa Prakash Nayak, Sabina O Nduaguba, 
Sandhya Neupane Kandel, Georges Nguefack-Tsague, 
Trang Huyen Nguyen, Molly R Nixon, Chukwudi A Nnaji, 
Jean Jacques Noubiap, Virginia Nuñez-Samudio, 
Thomas Elliot Nyirenda, Onome Bright Oghenetega, 
Andrew T Olagunju, Babayemi Oluwaseun Olakunde, 
Oluwatomi Funbi Owopetu, Mahesh P A, Jagadish Rao Padubidri, 
Smita Pakhale, Tarang Parekh, Fatemeh Pashazadeh Kan, 
Shrikant Pawar, Veincent Christian Filipino Pepito, 
Emmanuel K Peprah, Marina Pinheiro, Khem Narayan Pokhrel, 
Roman V Polibin, Richard Charles G Pollok, Maarten J Postma, 
Zahiruddin Quazi Syed, Amir Radfar, Raghu Anekal Radhakrishnan, 
Fakher Rahim, Vafa Rahimi-Movaghar, Shadi Rahimzadeh, 
Mosiur Rahman, Amir Masoud Rahmani, Pradhum Ram, 
Chhabi Lal Ranabhat, Priyanga Ranasinghe, Chythra R Rao, 
Sowmya J Rao, Priya Rathi, David Laith Rawaf, Salman Rawaf, 
Lemma Demissie Regassa, Inayat ur Rehman, Andre M N Renzaho, 
Nima Rezaei, Omid Rezahosseini, Mohammad Sadegh Rezai, 
Aziz Rezapour, Rezaul Karim Ripon, Voilet Rodrigues, 
Denis O Roshchin, Godfrey M Rwegerera, Umar Saeed, 
Sahar Saeedi Moghaddam, Rajesh Sagar, KM Saif-Ur-Rahman, 
Marwa Rashad Salem, Mehrnoosh Samaei, Abdallah M Samy, 
Milena M Santric-Milicevic, Satish Saroshe, Brijesh Sathian, 
Maheswar Satpathy, Monika Sawhney, Aletta Elisabeth Schutte, 
Allen Seylani, Masood Ali Shaikh, Mohammed Feyisso Shaka, 
Hina Shamshad, Morteza Shamsizadeh, Mohammed Shannawaz, 
Adithi Shetty, Jae Il Shin, K M Shivakumar, Jasvinder A Singh, 
Valentin Yurievich Skryabin, Anna Aleksandrovna Skryabina, 
Ranjani Somayaji, Sergey Soshnikov, Emma Elizabeth Spurlock, 
Dan J Stein, Mu’awiyyah Babale Sufiyan, Hooman Tadbiri, 
Birkneh Tilahun Tadesse, Eyayou Girma Tadesse, 
Animut Tagele Tamiru, Elvis Enowbeyang Tarkang, Nuno Taveira, 
Yohannes Tekalegn, Fisaha Haile Tesfay, Gizachew Assefa Tessema, 
Rekha Thapar, Marcos Roberto Tovani-Palone, Eugenio Traini, 
Bach Xuan Tran, Alexander C Tsai, Biruk Shalmeno Tusa, Saif Ullah, 
Chukwuma David Umeokonkwo, Bhaskaran Unnikrishnan, 
Sahel Valadan Tahbaz, Jorge Hugo Villafañe, 
Sergey Konstantinovitch Vladimirov, Bay Vo, Avina Vongpradith, 
Giang Thu Vu, Yasir Waheed, Richard G Wamai, Guan Wang, 
Yanzhong Wang, Paul Ward, Ronny Westerman, Andrea Sylvia Winkler, 
Lalit Yadav, Seyed Hossein Yahyazadeh Jabbari, Taklo Simeneh Yazie, 
Siyan Yi, Vahit Yiğit, Birhanu Wubale Yirdaw, Naohiro Yonemoto, 
Chuanhua Yu, Ismaeel Yunusa, Mikhail Sergeevich Zastrozhin, 
Anasthasia Zastrozhina, Zhi-Jiang Zhang, Alimuddin Zumla, 
Articles
e644 www.thelancet.com/hiv   Vol 8   October 2021
Joshua A Salomon, Jeffrey W Eaton, Mohsen Naghavi, 
Laura Dwyer-Lindgren, Haidong Wang, Stephen S Lim, Simon I Hay, 
Christopher J L Murray*, and Hmwe H Kyu*.
*Joint last authors.
Affiliations
Institute for Health Metrics and Evaluation (D Jahagirdar PhD, 
M K Walters BS, A Novotney MPH, E D Brewer BS, 
A Carter MPH, C Bisignano MPH, K Burkart PhD, X Dai PhD, 
Prof L Dandona MD, Prof R Dandona PhD, Prof L Degenhardt PhD, 
L Dwyer-Lindgren PhD, K S Ikuta MD, K E LeGrand MPH, C Lin BS, 
E R Maddison BS, M Moitra MPH, Prof A H Mokdad PhD, 
M R Nixon PhD, E E Spurlock BA, A Vongpradith BA, J W Eaton PhD, 
Prof M Naghavi MD, H Wang PhD, Prof S S Lim PhD, 
Prof S I Hay FMedSci, Prof C J L Murray DPhil, H H Kyu PhD), 
Department of Health Metrics Sciences, School of Medicine 
(K Burkart PhD, Prof R Dandona PhD, L Dwyer-Lindgren PhD, 
Prof A H Mokdad PhD, Prof M Naghavi MD, H Wang PhD, 
Prof S S Lim PhD, Prof S I Hay FMedSci, Prof C J L Murray DPhil, 
H H Kyu PhD), Division of Allergy and Infectious Diseases 
(K S Ikuta MD), Department of Global Health (S Kochhar MD), School 
of Social Work (J J Lee PhD), Department of Medicine (R Somayaji MD), 
University of Washington, Seattle, WA, USA; Vagelos College of 
Physicians and Surgeones (T D Frank MPH), Columbia University 
Medical Center, New York, NY, USA; Division of Data, Analytics, and 
Delivery for Impact (M H Biehl MPH), WHO, Geneva, Switzerland; 
Advanced Diagnostic and Interventional Radiology Research Centre 
(H Abbastabar PhD), Multiple Sclerosis Research Centre 
(S Eskandarieh PhD), School of Public Health (M Farahmand PhD), 
Department of Epidemiology and Biostatistics (Prof M Hosseini PhD, 
M Mansournia PhD), Paediatric Chronic Kidney Disease Research 
Centre (Prof M Hosseini PhD), Department of Psychiatry 
(R Jabbarinejad MD), Metabolomics and Genomics Research Centre 
(F Rahim PhD), Sina Trauma and Surgery Research Centre 
(Prof V Rahimi-Movaghar MD), Research Centre for 
Immunodeficiencies (Prof N Rezaei PhD), Non-Communicable Diseases 
Research Centre (S Saeedi Moghaddam MSc), Tehran University of 
Medical Sciences, Tehran, Iran; Department of Botany 
(E S Abhilash PhD), Sree Narayana Guru College Chelannur, Kozhikode, 
India; Clinical Sciences Department (E Abu-Gharbieh PhD), Mass 
Communication Department (A Makki PhD), University of Sharjah, 
Sharjah, United Arab Emirates; Department of Health-Care Policy and 
Research, Weill Cornell Medical College in Qatar, Doha, Qatar 
(Prof L J Abu-Raddad PhD); Department of Population Medicine, Cardiff 
University, Cardiff, UK (V Adekanmbi PhD); Department of Community 
Health and Epidemiology, University of Saskatchewan, Saskatoon, SK, 
Canada (D A Adeyinka MPH); Department of Public Health, Federal 
Ministry of Health, Abuja, Nigeria (D A Adeyinka MPH); Department of 
Midwifery, Karya Husada Institute of Health Sciences, Kediri, Indonesia 
(Q E S Adnani PhD); Department of Midwifery, Auckland University of 
Technology, Auckland, New Zealand (Q E S Adnani PhD); Department 
of Community Medicine, King Edward Memorial Hospital, Lahore, 
Pakistan (Prof S Afzal PhD); Department of Public Health, Public 
Health Institute, Lahore, Pakistan (Prof S Afzal PhD); Mother and Child 
Care Research Centre (S Aghababaei PhD), Faculty of Nursing and 
Midwifery (S Aghababaei PhD), Department of Midwifery 
(S Masoumi PhD), Hamadan University of Medical Sciences, Hamadan, 
Iran; The Australian Centre for Public and Population Health Research, 
University of Technology Sydney, Sydney, NSW, Australia 
(B O Ahinkorah MPH, E K Ameyaw MPhil); Foundation University 
Medical College, Foundation University Islamabad, Islamabad, Pakistan 
(S Ahmad PhD, Prof Y Waheed PhD); Lincoln Medical School, 
Universities of Nottingham and Lincoln, Lincoln, UK (K Ahmadi PhD); 
School of Advanced Technologies in Medicine, Shahid Beheshti 
University of Medical Sciences, Tehran, Iran (S Ahmadi PhD); Infectious 
and Tropical Diseases Research Centre, Tabriz University of Medical 
Sciences, Tabriz, Iran (E Ahmadpour PhD); Department of 
Epidemiology (M B Ahmed MPH), School of Pharmacy 
(H K Kebede MSc), Jimma University, Jimma, Ethiopia; Australian 
Centre for Precision Health, University of South Australia, Adelaide, SA, 
Australia (M B Ahmed MPH); Department of Computer Science and 
Engineering, University of Kurdistan Hewler, Erbil, Iraq 
(T Ahmed Rashid PhD); Database Technology Department 
(Y Ahmed Salih PhD), College of Informatics (Y Ahmed Salih PhD), 
Sulaimani Polytechnic University, Sulaymaniyah, Iraq; Department of 
Medical Laboratory Sciences (A Aklilu MSc), Department of Biomedical 
Sciences (E G Tadesse MSc), Arba Minch University, Arba Minch, 
Ethiopia; School of Mathematical Sciences (T Akram PhD), School of 
Pharmaceutical Sciences (R Hussain PhD), University of Science 
Malaysia, Penang, Malaysia; Department of Public Health, 
The Intercountry Centre for Oral Health for Africa, Jos, Nigeria 
(C J Akunna DMD); Department of Public Health, Federal Ministry of 
Health, Garki, Nigeria (C J Akunna DMD); Geriatric and Long-Term 
Care Department (H Al Hamad MD, B Sathian PhD), Rumailah 
Hospital (H Al Hamad MD), Hamad Medical Corporation, Doha, Qatar; 
Mayo Evidence-based Practice Center, Mayo Clinic Foundation for 
Medical Education and Research, Rochester, MN, USA (F Alahdab MSc); 
Environmental Health Department (S M A Dahlawi PhD), Forensic 
Medicine Division (Prof R G Menezes MD), Imam Abdulrahman Bin 
Faisal University, Dammam, Saudi Arabia (F M Alanezi PhD); 
International Centre for Health Economics, Management, and Policy, 
National Research University Higher School of Economics, 
St Petersburg, Russia (E A Aleksandrova PhD, P Meylakhs PhD); Faculty 
of Health Sciences (K A Alene MPH), School of Public Health 
(B A Dachew PhD, T R Miller PhD, G A Tessema PhD), Curtin 
University, Perth, WA, Australia; Wesfarmers Centre of Vaccines and 
Infectious Diseases, Telethon Kids Institute, Perth, WA, Australia 
(K A Alene MPH); Department of Biological Sciences, National 
University of Medical Sciences, Rawalpindi, Pakistan (L Ali PhD); Health 
Management and Economics Research Centre (V Alipour PhD, 
J Arabloo PhD, S Azari PhD, A Ghashghaee BSc, 
M Hosseinzadeh PhD, A Rezapour PhD), Department of Health 
Economics (V Alipour PhD), Department of Medical Laboratory Sciences 
(F Dorostkar PhD), Student Research Committee (A Ghashghaee BSc), 
Minimally Invasive Surgery Research Centre (A Kabir MD), Iran 
University of Medical Sciences, Tehran, Iran (F Pashazadeh Kan BSN); 
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia 
(S Almustanyir MD, Prof Z A Memish MD); Research and Innovation 
Centre (Prof Z A Memish MD), Ministry of Health, Riyadh, Saudi Arabia 
(S Almustanyir MD); Research Group in Hospital Management and 
Health Policies, Universidad de la Costa, Barranquilla, Colombia 
(Prof N Alvis-Guzman PhD); Research Group in Health Economics, 
University of Cartagena, Cartagena, Colombia 
(Prof N Alvis-Guzman PhD); Department of Population and Behavioural 
Sciences, University of Health and Allied Sciences, Ho, Ghana 
(H Amu PhD, E E Tarkang PhD); Cardiology Department, Carol Davila 
University of Medicine and Pharmacy, Bucharest, Romania 
(C Andrei PhD); Department of Statistics and Econometrics, Bucharest 
University of Economic Studies, Bucharest, Romania 
(Prof T Andrei PhD, I Glăvan PhD, A Mirica PhD); Department of 
Parasitology (D Anvari PhD), Paediatric Infectious Diseases Research 
Centre (Prof M Rezai MD), Mazandaran University of Medical Sciences, 
Sari, Iran; Department of Parasitology, Iranshahr University of Medical 
Sciences, Iranshahr, Iran (D Anvari PhD); Department of Public Health, 
Birmingham City University, Birmingham, UK (O Aremu PhD); 
Department of Maternal and Child Health, Sultan Qaboos University, 
Muscat, Oman (J Arulappan DSc); Department of Health System and 
Health Economics (D D Atnafu MPH), Department of Internal Medicine 
(Y M Bezabih MD), Department of Nursing (A B Dagnew MSc), 
Department of Medical Laboratory Sciences (F M Demeke MSc), 
Department of Paediatrics and Child Health Nursing 
(A Endalamaw MSc), Department of Reproductive Health and 
Population Studies (E W Mengesha MPH), Bahir Dar University, Bahir 
Dar, Ethiopia (W M Bezabhe BSc); The Judith Lumley Centre 
(B Ayala Quintanilla PhD), School of Psychology and Public Health 
(M Islam PhD), La Trobe University, Melbourne, VIC, Australia; 
San Martin de Porres University, Lima, Peru (B Ayala Quintanilla PhD); 
Department of Pharmacology and Toxicology (M A Ayza MSc), 
Department of Epidemiology (H A Gesesew PhD), School of Public 
Health (F H Tesfay PhD), Mekelle University, Mekelle, Ethiopia; 
Kasturba Medical College, Mangalore (D B B MD, R Holla MD, 
A Kamath MD, J Padubidri MD, P Rathi MD, Prof B Unnikrishnan MD) 
Prof B Unnikrishnan MD), Centre for Bio Cultural Studies 
Articles
www.thelancet.com/hiv   Vol 8   October 2021 e645
(P Hoogar PhD), Manipal College of Dental Sciences 
(Prof A I Narayana PhD, Prof R A Radhakrishnan PhD), Department of 
Community Medicine (C R Rao MD), Manipal Academy of Higher 
Education, Manipal, India (A Kamath MD); Department of 
Hypertension, Medical University of Lodz, Lodz, Poland 
(Prof M Banach PhD); Polish Mothers’ Memorial Hospital Research 
Institute, Lodz, Poland (Prof M Banach PhD); Heidelberg Institute of 
Global Health, Heidelberg University, Heidelberg, Germany 
(Prof T W Bärnighausen MD, B Moazen MSc); T H Chan School of 
Public Health (Prof T W Bärnighausen MD, I Yunusa PhD), Center for 
Primary Care (S Basu PhD), Harvard University, Boston, MA, USA; 
Academic Unit of Obstetrics and Gynaecology (F Barra MD), 
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, 
Maternal, and Child Health (Prof S Ferrero PhD), University Eye Clinic 
(L Ferro Desideri MD), University of Genoa, Genoa, Italy; Department of 
Public and Environmental Health, University of The Gambia, Brikama, 
The Gambia (A Barrow MPH); Epidemiology and Disease Control Unit, 
Ministry of Health, Kotu, The Gambia (A Barrow MPH); School of 
Public Health (S Basu PhD), Department of Primary Care and Public 
Health (Prof A Majeed MD, Prof S Rawaf MD), WHO Collaborating 
Centre for Public Health Education and Training (D L Rawaf MD), 
Department of Infectious Disease Epidemiology (J W Eaton PhD), 
Imperial College London, London, UK; Department of Psychiatry, 
Charles R Drew University of Medicine and Science, Los Angeles, CA, 
USA (Prof S Bazargan-Hejazi BEP); Department of Psychiatry and 
Biobehavioral Sciences, University of California Los Angeles, 
Los Angeles, CA, USA (Prof S Bazargan-Hejazi BEP); Department of 
Midwifery (H G Belay MSc), Department of Pharmacy (T S Yazie MSc), 
Debre Tabor University, Debre Tabor, Ethiopia; HIV and TB Research 
Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia 
(T M Berheto MPH); University of Tasmania, Tasmania, VIC, Australia 
(W M Bezabhe BSc); One Health, University of Nantes, Nantes, France 
(Y M Bezabih MD); Department of Social and Clinical Pharmacy, 
Charles University, Hradec Kralova, Czech Republic 
(A S Bhagavathula PharmD); Institute of Public Health 
(A S Bhagavathula PharmD), Department of Medical Microbiology and 
Immunology (Prof G Khan PhD), United Arab Emirates University, 
Al Ain, United Arab Emirates; Department of Anatomy, Government 
Medical College Pali, Pali, India (Prof N Bhardwaj MD); Department of 
Community Medicine and Family Medicine (P Bhardwaj MD), School of 
Public Health (P Bhardwaj MD), Department of Pharmacology 
(J Charan MD), Department of Forensic Medicine and Toxicology 
(T Kanchan MD), All India Institute of Medical Sciences, Jodhpur, India; 
Department of Statistical and Computational Genomics, National 
Institute of Biomedical Genomics, Kalyani, India (K Bhattacharyya MSc); 
Department of Statistics, University of Calcutta, Kolkata, India 
(K Bhattacharyya MSc); Institute of Soil and Environmental Sciences, 
University of Agriculture, Faisalabad, Pakistan (S Bibi PhD, 
S Ullah PhD); Social Determinants of Health Research Centre, Babol 
University of Medical Sciences, Babol, Iran (A Bijani PhD); Department 
of Public Health Medicine, University of KwaZulu-Natal, Durban, South 
Africa (O A Bolarinwa MSc, T G Ginindza PhD); Department of Internal 
Medicine (A Boloor MD), Department of Community Medicine 
(N Joseph MD, N Kumar MD, R Thapar MD), Department of Obstetrics 
and Gynaecology (A Shetty MS), Manipal Academy of Higher Education, 
Mangalore, India; Department of Mental Health, Human Research and 
Development Centre, Bukhara, Uzbekistan (A A Boltaev MD); 
Department of Epidemiology and Evidence-Based Medicine 
(Prof N I Briko DSc, E V Glushkova PhD, V A Korshunov PhD, 
R V Polibin PhD), Department of Information and Internet Technologies 
(S K Vladimirov PhD), I M Sechenov First Moscow State Medical 
University, Moscow, Russia; Department of Woman and Child Health 
and Public Health, Fondazione Policlinico Universitario A Gemelli 
IRCCS (Agostino Gemelli University Polyclinic IRCCS), Rome, Italy 
(D Buonsenso MD); Global Health Research Institute, Università 
Cattolica del Sacro Cuore, Roma, Italy (D Buonsenso MD); School of 
Public Health and Health Systems, University of Waterloo, Waterloo, 
ON, Canada (Z A Butt PhD); Al Shifa School of Public Health, Al Shifa 
Trust Eye Hospital, Rawalpindi, Pakistan (Z A Butt PhD); Program in 
Physical Therapy, Washington University in St Louis, St Louis, MO, 
USA (C Cao MPH); Department of Microbiology and Infection Control, 
Medanta Medicity, Gurugram, India (S Chatterjee MD); Department of 
Public Health, Texila American University, Georgetown, Guyana 
(S Chattu PhD); Department of Medicine, University of Toronto, 
Toronto, ON, Canada (V Chattu MD); Global Institute of Public Health, 
Thiruvananthapuram, India (V Chattu MD); Department of Community 
Medicine, Datta Meghe Institute of Medical Sciences, Wardha, India 
(Prof S G Choudhari MD, Prof A M Gaidhane MD, 
Prof Z Quazi Syed PhD); Centre for Biomedicine and Community 
Health, VNU-International School, Hanoi, Vietnam (D Chu PhD); 
Department of Chemical Sciences (R A S Couto MD), Institute for 
Research and Innovation in Health (J das Neves PhD), Institute of 
Biomedical Engineering (J das Neves PhD), Department of Chemistry 
(M Pinheiro PhD), University of Porto, Porto, Portugal; Department of 
Psychology, University of the Free State, Park West, South Africa 
(R G Cowden PhD); Department of Epidemiology (B A Dachew PhD), 
Department of Surgical Nursing (A A Desta MSc), Department of 
Clinical Pharmacy (E Gebreyohannes MSc), School of Medicine 
(A G Mersha MD), Department of Midwifery (A T Tamiru MSc, 
B W Yirdaw MSc), University of Gondar, Gondar, Ethiopia; School of 
Public Health, Walailak University, Nakhon Si Thammarat, Thailand 
(O Dadras DrPH); Graduate School of Medicine, Kyoto University, 
Kyoto, Japan (O Dadras DrPH); Public Health Foundation of India, 
Gurugram, India (Prof L Dandona MD, Prof R Dandona PhD, 
G Kumar PhD, D K Lal MD); Indian Council of Medical Research, 
New Delhi, India (Prof L Dandona MD); National Drug and Alcohol 
Research Centre (Prof L Degenhardt PhD), School of Public Health and 
Community Medicine (Prof A E Schutte PhD), University of New South 
Wales, Sydney, NSW, Australia; National Centre for AIDS and STD 
Control, Save the Children, Kathmandu, Nepal (K Deuba DrPH); 
Department of Global Public Health, Karolinska Institute, Stockholm, 
Sweden (K Deuba DrPH); Department of Community Medicine, 
Dr Baba Sahib Ambedkar Medical College and Hospital, Delhi, India 
(D Dhamnetiya MD, R P Jha MSc); Department of Microbiology, Far 
Western University, Mahendranagar, Nepal (G P Dhungana MSc); 
Department of Epidemiology and Biostatistics, Shahroud University of 
Medical Sciences, Shahroud, Iran (M Dianatinasab MSc); Department of 
Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran 
(M Dianatinasab MSc); Centre of Complexity Sciences, National 
Autonomous University of Mexico, Mexico City, Mexico 
(Prof D Diaz PhD); Faculty of Veterinary Medicine and Zootechnics, 
Autonomous University of Sinaloa, Culiacán Rosales, Mexico 
(Prof D Diaz PhD); Development of Research and Technology Centre, 
Ministry of Health and Medical Education, Tehran, Iran 
(S Djalalinia PhD); Institute for Global Health Innovations 
(L P Doan MSc, T H Nguyen MSc), Faculty of Medicine 
(L P Doan MSc, T H Nguyen MSc), Duy Tan University, Da Nang, 
Vietnam; School of Health Sciences (H A Edinur PhD), Universiti Sains 
Malaysia (University of Science Malaysia), Kubang Kerian, Malaysia; 
Centre Clinical Epidemiology and Biostatistics (A Effiong MB), School of 
Medicine and Public Health (A G Mersha MD), University of Newcastle, 
Newcastle, NSW, Australia; Division of Urology, Children’s Hospital of 
Philadelphia, Philadelphia, PA, USA (S Eftekharzadeh MD); Reference 
Laboratory of Egyptian Universities-Cairo, Ministry of Higher Education 
and Scientific Research, Cairo, Egypt (Prof M El Sayed Zaki PhD); 
School of Behavioural Sciences, Mahatma Gandhi University of Medical 
Sciences and Technology, Kottayam, India (R Elayedath MSc); Faculty of 
Medicine, University of Tripoli, Tripoli, Libya (M Elhadi MD); 
Department of Neurology (S I El-Jaafary MD), Department of Endemic 
Medicine and Hepatogastroenterology (A Elsharkawy MD), Cairo 
University, Cairo, Egypt; World Health Programme (Z El-Khatib PhD), 
Université du Québec en Abitibi-Témiscamingue (University of Quebec 
in Abitibi-Témiscamingue), Quebec, QC, Canada; Public Health 
Department, St Paul’s Hospital Millennium Medical College, Addis 
Ababa, Ethiopia (A Y Endries MPH); Institute for Health Science 
Research Germans Trias i Pujol, Autonomous University of Barcelona, 
Badalona, Spain (I J Ezeonwumelu MSc); IrsiCaixa AIDS Research 
Institute, Badalona, Spain (I J Ezeonwumelu MSc); Department of 
Virology, Pasteur Institute of Morocco, Casablanca, Morocco 
(S Ezzikouri PhD); Department of Health Policy and Administration, 
University of the Philippines Manila, Manila, Philippines 
(E A Faraon MD); Satcher Health Leadership Institute, Morehouse 
Articles
e646 www.thelancet.com/hiv   Vol 8   October 2021
School of Medicine, Atlanta, GA, USA (A O Fasanmi PhD); School of 
Medicine (A O Fasanmi PhD), Department of Cardiology (P Ram MD), 
Emory University, Atlanta, GA, USA; Psychiatry Department, Kaiser 
Permanente, Fontana, CA, USA (I Filip MD); School of Health Sciences, 
A T Still University, Mesa, AZ, USA (I Filip MD); Institute of 
Gerontological Health Services and Nursing Research, Ravensburg-
Weingarten University of Applied Sciences, Weingarten, Germany 
(F Fischer PhD); Department of Child Dental Health, Obafemi Awolowo 
University, Ile-Ife, Nigeria (Prof M O Folayan FWACS); Department of 
Medical Parasitology, Abadan Faculty of Medical Sciences, Abadan, Iran 
(M Foroutan PhD); Department of Dermatology, Kobe University, Kobe, 
Japan (T Fukumoto PhD); Department of Cardiovascular Medicine 
(M M Gad MD), Department of Internal Medicine (V Jain MD), Lerner 
Research Institute (X Liu PhD), Cleveland Clinic, Cleveland, OH, USA; 
Gillings School of Global Public Health, University of North Carolina 
Chapel Hill, Chapel Hill, NC, USA (M M Gad MD); Community 
Medicine Department, Bayero University, Kano, Nigeria 
(M A Gadanya FMCPH); Department of Community Medicine, Aminu 
Kano Teaching Hospital, Kano, Nigeria (M A Gadanya FMCPH); 
Department of Radiology, King Edward Memorial Hospital, Mumbai, 
India (T Garg MBBS); Department of Nursing, Wollega University, 
Nekemte, Ethiopia (R T Gayesa MSc); Division of Pharmacy, University 
of Western Australia, Perth, WA, Australia (E Gebreyohannes MSc); 
College of Medicine and Public Health (H A Gesesew PhD, 
Prof P Ward PhD), Health and Social Care Economics Group 
(C Mpundu-Kaambwa PhD), Southgate Institute for Health and Society 
(F H Tesfay PhD), Flinders University, Adelaide, SA, Australia; School of 
Psychology (A Getachew Obsa MA), School of Public Health 
(W A Manamo MSc), Addis Ababa University, Addis Ababa, Ethiopia; 
Infectious Disease Research Centre (Prof K Ghadiri MD), Paediatric 
Department (Prof K Ghadiri MD), Kermanshah University of Medical 
Sciences, Kermanshah, Iran; Faculty of Allied Health Sciences 
(Prof S Gilani PhD), University Institute of Public Health 
(A A Malik PhD), The University of Lahore, Lahore, Pakistan; Afro-Asian 
Institute, Lahore, Pakistan (Prof S Gilani PhD); Health Systems and 
Policy Research, Indian Institute of Public Health, Gandhinagar, India 
(M Golechha PhD); Department of Microbiology 
(Prof H C Gugnani PhD), Department of Epidemiology 
(Prof H C Gugnani PhD), Saint James School of Medicine, The Valley, 
Anguilla; Department of Public Health, Torrens University, Melbourne, 
VIC, Australia (B Gupta PhD); Toxicology Department, Shriram Institute 
for Industrial Research, Delhi, India (S Gupta MSc); School of Medicine, 
Deakin University, Geelong, VIC, Australia (V Gupta PhD); Department 
of Clinical Medicine, Macquarie University, Sydney, NSW, Australia 
(Prof V K Gupta PhD); School of Health and Environmental Studies, 
Hamdan Bin Mohammed Smart University, Dubai, United Arab 
Emirates (Prof S Hamidi DrPH); WHO Collaborating Centre for HIV 
Strategic Information, University of Zagreb, Zagreb, Croatia 
(S Handanagic MD); Research and Scientific Studies Unit, Jazan 
University, Jazan, Saudi Arabia (S Haque PhD); Medical Research Unit 
(H Harapan PhD), Universitas Syiah Kuala (Syiah Kuala University), 
Banda Aceh, Indonesia; Department of Epidemiology, Universitas 
Airlangga, Surabaya, Indonesia (A Hargono Dr); Department of Zoology 
and Entomology, Al Azhar University, Cairo, Egypt 
(A I Hasaballah PhD); Department of Public Health, Jigjiga University, 
Jijiga, Ethiopia (A Hashi PhD); Centre for International Health 
(S Hassan MPhil), Bergen Centre for Ethics and Priority Setting 
(S Hassan MPhil), University of Bergen, Bergen, Norway; 
Gastrointestinal and Liver Diseases Research Centre 
(S Hassanipour PhD), Caspian Digestive Disease Research Centre 
(S Hassanipour PhD), Guilan University of Medical Sciences, Rasht, 
Iran; Institute of Pharmaceutical Sciences, University of Veterinary and 
Animal Sciences, Lahore, Pakistan (K Hayat MS); Department of 
Pharmacy Administration and Clinical Pharmacy, Xian Jiaotong 
University, Xian, China (K Hayat MS); Centre for Health Systems 
Research, National Institute of Public Health, Cuernavaca, Mexico 
(Prof I Heredia-Pi DipSocSc); Department of Applied Microbiology, Taiz 
University, Taiz, Yemen (K Hezam PhD); Department of Microbiology, 
Nankai University, Tianjin, China (K Hezam PhD); NHMRC Clinical 
Trial Centre (M E Hoque PhD), Save Sight Institute (H Kandel PhD), 
University of Sydney, Sydney, NSW, Australia; Faculty of Medicine of 
Tunis, University Tunis El Manar, Tunis, Tunisia (Prof M Hsairi MPH); 
Department of Health Promotion and Education (S E Ibitoye MPH), 
Department of Community Medicine (O S Ilesanmi PhD), Department 
of Obstetrics and Gynaecology (O B Oghenetega MSc), University of 
Ibadan, Ibadan, Nigeria; Infectious Diseases Department, Bashkir State 
Medical University, Ufa, Russia (B Idrisov MD); Laboratory of Public 
Health Indicators Analysis and Health Digitalisation, Moscow Institute 
of Physics and Technology, Moscow, Russia (B Idrisov MD, 
S Soshnikov PhD); Department of Community Medicine 
(O S Ilesanmi PhD), Department of Total Quality Management 
(O F Owopetu MSc), University College Hospital, Ibadan, Nigeria; 
Faculty of Medicine (I M Ilic PhD, Prof M M Santric-Milicevic PhD), 
School of Public Health and Health Management 
(Prof M M Santric-Milicevic PhD), University of Belgrade, Belgrade, 
Serbia; Department of Epidemiology, University of Kragujevac, 
Kragujevac, Serbia (Prof M D Ilic PhD); Independent Consultant, Tabriz, 
Iran (S N Irvani MD); Department of Clinical Pharmacy, MAHSA 
University, Bandar Saujana Putra, Malaysia (Prof N Ismail PhD); 
Department of Health Management, University of Hail, Hail, 
Saudi Arabia (R Itumalla PhD); Knowledge Translation Program, Centre 
for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada 
(I O Iyamu MD); School of Population and Public Health, University of 
British Columbia, Vancouver, BC, Canada (I O Iyamu MD); Department 
of Physical Medicine and Rehabilitation, Northwestern University, 
Chicago, IL, USA (R Jabbarinejad MD); Department of Physiology 
(R Jayawardena PhD), Department of Pharmacology 
(P Ranasinghe PhD), University of Colombo, Colombo, Sri Lanka; 
School of Exercise and Nutrition Sciences, Queensland University of 
Technology, Brisbane, QLD, Australia (R Jayawardena PhD); Department 
of Community Medicine, Banaras Hindu University, Varanasi, India 
(R P Jha MSc); School of Public Health, University College Cork, Cork, 
Ireland (Z Kabir PhD); Institute for Prevention of Non-communicable 
Diseases (R Kalhor PhD), Health Services Management Department 
(R Kalhor PhD), Qazvin University of Medical Sciences, Qazvin, Iran; 
Dermatology Department, King Faisal University, Hofuf, Saudi Arabia 
(F Kaliyadan MD); Sydney Eye Hospital, South Eastern Sydney Local 
Health District, Sydney, NSW, Australia (H Kandel PhD); School of 
Midwifery (G Kassahun MSc), Department of Paediatrics 
(B T Tadesse MD), Hawassa University, Hawassa, Ethiopia; Centre for 
Tropical Diseases and Global Health, Catholic University of Bukavu, 
Bukavu, Democratic Republic of the Congo (P D Katoto PhD); 
Department of Global Health, Stellenbosch University, Cape Town, 
South Africa (P D Katoto PhD, T E Nyirenda MD); International 
Research Center of Excellence, Institute of Human Virology Nigeria, 
Abuja, Nigeria (G A Kayode PhD); Julius Centre for Health Sciences and 
Primary Care (G A Kayode PhD), Institute for Risk Assessment Sciences 
(E Traini MSc), Utrecht University, Utrecht, Netherlands; Department of 
Public Health, Ambo University, Ambo, Ethiopia (E M Kebede MPH); 
Amity Institute of Forensic Sciences, Amity University, Noida, India 
(H Khajuria PhD, B P Nayak PhD); School of Food and Agricultural 
Sciences, University of Management and Technology, Lahore, Pakistan 
(N Khalid PhD); Department of Epidemiology and Biostatistics, Health 
Services Academy, Islamabad, Pakistan (E A Khan MPH); Faculty of 
Health and Wellbeing, Sheffield Hallam University, Sheffield, UK 
(K Khatab PhD); College of Arts and Sciences, Ohio University, 
Zanesville, OH, USA (K Khatab PhD); Department of Genomics and 
Digital Health, Samsung Advanced Institute for Health Sciences and 
Technology, Seoul, South Korea (M Kim MD); Public Health Center, 
Ministry of Health and Welfare, Wando, South Korea (M Kim MD); 
School of Traditional Chinese Medicine, Xiamen University Malaysia, 
Sepang, Malaysia (Y Kim PhD); School of Health Sciences, Kristiania 
University College, Oslo, Norway (Prof A Kisa PhD); Department of 
Global Community Health and Behavioral Sciences, Tulane University, 
New Orleans, LA, USA (Prof A Kisa PhD); Department of Nursing and 
Health Promotion, Oslo Metropolitan University, Oslo, Norway 
(S Kisa PhD); Global Health-Care Consulting, New Delhi, India 
(S Kochhar MD); Department of Internal and Pulmonary Medicine, 
Sheri Kashmir Institute of Medical Sciences, Srinagar, India 
(Prof P A Koul MD); Kasturba Medical College, Udupi, India 
(S Koulmane Laxminarayana MD); Biomedical Research Networking 
Centre for Mental Health Network (CIBERSAM), San Juan de Dios 
Articles
www.thelancet.com/hiv   Vol 8   October 2021 e647
Sanitary Park, Sant Boi de Llobregat, Spain (A Koyanagi MD); Catalan 
Institution for Research and Advanced Studies (ICREA), Barcelona, 
Spain (A Koyanagi MD); Department of Anthropology, Panjab 
University, Chandigarh, India (K Krishan PhD); Department of 
Demography (Prof B Kuate Defo PhD), Department of Social and 
Preventive Medicine (Prof B Kuate Defo PhD), University of Montreal, 
Montreal, QC, Canada; Department of Psychiatry (M Kumar PhD), 
School of Public Health (R G Wamai PhD), University of Nairobi, 
Nairobi, Kenya; Division of Psychology and Language Sciences 
(M Kumar PhD), Department of Infection (Prof A Zumla PhD), 
University College London, London, UK; Department of Biochemistry 
and Biotechnology, Kwame Nkrumah University of Science and 
Technology, Kumasi, Ghana (A Kwarteng PhD); Unit of Genetics and 
Public Health (Prof I Landires MD), Unit of Microbiology and Public 
Health (V Nuñez-Samudio PhD), Institute of Medical Sciences, Las 
Tablas, Panama; Department of Public Health (V Nuñez-Samudio PhD), 
Ministry of Health, Herrera, Panama (Prof I Landires MD); Department 
of Otorhinolaryngology, Father Muller Medical College, Mangalore, India 
(S Lasrado MS); Robinson Research Institute (Z S Lassi PhD), Centre for 
Heart Rhythm Disorders (J Noubiap MD), School of Public Health 
(G A Tessema PhD), Adelaide Medical School (L Yadav PhD), University 
of Adelaide, Adelaide, SA, Australia; Barcelona Institute for Global 
Health, Barcelona, Spain (Prof J V Lazarus PhD); Department of 
Medicine (Prof Y Lee PhD), School of Medical Sciences 
(Prof Y Lee PhD), University of Science Malaysia, Kota Bharu, Malaysia; 
Department of Quantitative Health Science, Case Western Reserve 
University, Cleveland, OH, USA (X Liu PhD); Radiology Department, 
Egypt Ministry of Health and Population, Mansoura, Egypt 
(H Magdy Abd El Razek MD); Grants, Innovation, and Product 
Development Unit (P W Mahasha PhD), Risk and Resilience in Mental 
Disorders Unit (Prof D J Stein MD), South African Medical Research 
Council, Cape Town, South Africa (C A Nnaji MPH); Rabigh Faculty of 
Medicine, King Abdulaziz University, Jeddah, Saudi Arabia 
(A A Malik PhD); Campus Caucaia, Federal Institute of Education, 
Science and Technology of Ceará, Caucaia, Brazil 
(F R Martins-Melo PhD); Department of Statistics, Debre Markos 
University, Debre Markos, Ethiopia (H E Merie MSc); Clinical 
Microbiology and Parasitology Unit, Dr Zora Profozic Polyclinic, Zagreb, 
Croatia (T Mestrovic PhD); University Centre Varazdin, University 
North, Varazdin, Croatia (T Mestrovic PhD); The Center for Drug Use 
and HIV Research (P Meylakhs PhD), School of Global Public Health 
(E K Peprah PhD), New York University, New York, NY, USA; 
Department of Communication and Journalism, Autonomous 
University of Barcelona, Barcelona, Spain (N Mheidly BA); Pacific 
Institute for Research & Evaluation, Calverton, MD, USA 
(T R Miller PhD); Institute of Addiction Research, Frankfurt University 
of Applied Sciences, Frankfurt, Germany (B Moazen MSc); Internal 
Medicine Department, King Saud University, Riyadh, Saudi Arabia 
(Y Mohammad MD); Department of Information Technology, Lebanese 
French University, Erbil, Iraq (M Mohammadi PhD); Department of 
Biology, University of Jeddah, Jeddah, Saudi Arabia 
(A Mohammed PhD); Department of Biomolecular Sciences, University 
of Mississippi, Oxford, MS, USA (S Mohammed MSc); Department of 
Pharmacy, Mizan-Tepi University, Mizan, Ethiopia (S Mohammed MSc); 
Health Systems and Policy Research Unit (S Mohammed PhD), 
Department of Community Medicine (M B Sufiyan MD), Ahmadu Bello 
University, Zaria, Nigeria; Department of Health-Care Management, 
Technical University of Berlin, Berlin, Germany (S Mohammed PhD); 
Faculty of Life Sciences and Medicine (M Molokhia PhD), School of 
Population Health and Environmental Sciences (Y Wang PhD), King’s 
College London, London, UK; Department of Computer Science and 
Engineering, Pabna University of Science and Technology, Pabna, 
Bangladesh (M Moni PhD); Social Determinants of Health Research 
Centre (G Moradi PhD, Y Moradi PhD), Department of Epidemiology 
and Biostatistics (G Moradi PhD), Kurdistan University of Medical 
Sciences, Sanandaj, Iran; Department of Epidemiology and Biostatistics 
(S Mubarik MS, Prof C Yu PhD), School of Medicine (Z Zhang PhD), 
Wuhan University, Wuhan, China; Scientific Communications 
Department, Invitae, Boulder, CO, USA (S B Munro PhD); College of 
Medicine and Public Health, Flinders University, Adeaide, SA, Australia 
(L Mwanri PhD); Department of Epidemiology, University of Pittsburgh, 
Pittsburgh, PA, USA (Prof J B Nachega PhD); Department of 
Epidemiology (Prof J B Nachega PhD), Johns Hopkins University, 
Baltimore, MD, USA (H Tadbiri MD); Research and Analytics 
Department, Initiative for Financing Health and Human Development, 
Chennai, India (A J Nagarajan Mtech); Department of Research and 
Analytics, Bioinsilico Technologies, Chennai, India 
(A J Nagarajan Mtech); Department of Biotechnology, University of 
Central Punjab, Lahore, Pakistan (M Naveed PhD); Pharmaceutical 
Outcomes and Policy Department, University of Florida, Gainesville, FL, 
USA (S O Nduaguba PhD); Bupa Clemton Park, Bupa, Sydney, NSW, 
Australia (S Neupane Kandel BSN); Department of Public Health, 
University of Yaoundé I, Yaoundé, Cameroon (G Nguefack-Tsague PhD); 
School of Public Health and Family Medicine, University of Cape Town, 
Cape Town, South Africa (C A Nnaji MPH); European and Developing 
Countries Clinical Trials Partnership, European Commission, Cape 
Town, South Africa (T E Nyirenda MD); Department of Psychiatry and 
Behavioural Neurosciences, McMaster University, Hamilton, ON, 
Canada (A T Olagunju MD); Department of Psychiatry, University of 
Lagos, Lagos, Nigeria (A T Olagunju MD); Community Prevention and 
Care Services, National AIDS Control Committee, Abuja, Nigeria 
(B O Olakunde PhD); Department of Respiratory Medicine, Jagadguru 
Sri Shivarathreeswara Academy of Health Education and Research, 
Mysore, India (Prof M P A DNB); Department of Medicine, Ottawa 
Hospital Research Institute, Ottawa, ON, Canada (S Pakhale MD); 
Department of Health Administration and Policy, George Mason 
University, Fairfax, VA, USA (T Parekh MSc); Department of Genetics, 
Yale University, New Haven, CT, USA (S Pawar PhD); Centre for 
Research and Innovation, Ateneo De Manila University, Pasig City, 
Philippines (V F Pepito MSc); HIV and Mental Health Department, 
Integrated Development Foundation Nepal, Kathmandu, Nepal 
(K N Pokhrel PhD); Institute of Infection and Immunity, St George’s 
University of London, London, UK (R C G Pollok FRCP); University 
Medical Centre Groningen (Prof M J Postma PhD), School of Economics 
and Business (Prof M J Postma PhD), University of Groningen, 
Groningen, Netherlands; College of Medicine, University of Central 
Florida, Orlando, FL, USA (A Radfar MD); Thalassaemia and 
Haemoglobinopathy Research Centre, Ahvaz Jundishapur University of 
Medical Sciences, Ahvaz, Iran (F Rahim PhD); Department of Natural 
Science, Middlesex University, London, UK (S Rahimzadeh MSc); 
Department of Population Science and Human Resource Development, 
University of Rajshahi, Rajshahi, Bangladesh (M Rahman DrPH); Future 
Technology Research Center, National Yunlin University of Science and 
Technology, Yunlin, Taiwan (A Rahmani PhD); Research Department, 
Policy Research Institute, Kathmandu, Nepal (C L Ranabhat PhD); 
Health and Public Policy Department, Global Centre for Research and 
Development, Kathmandu, Nepal (C L Ranabhat PhD); Department of 
Oral Pathology, Srinivas Institute of Dental Sciences, Mangalore, India 
(S Rao MDS); NIHR-Biomedical Research Centre (Prof A Zumla PhD), 
University College London Hospitals, London, UK (D L Rawaf MD); 
Academic Public Health England, Public Health England, London, UK 
(Prof S Rawaf MD); Department of Epidemiology and Biostatistics, 
Haramaya University, Harar, Ethiopia (L D Regassa MPH); Department 
of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan 
(I Rehman PhD); School of Medicine (Prof A M N Renzaho PhD), 
Translational Health Research Institute (Prof A M N Renzaho PhD), 
Western Sydney University, Campbelltown, NSW, Australia; Network of 
Immunity in Infection, Malignancy, and Autoimmunity, Universal 
Scientific Education and Research Network, Tehran, Iran 
(Prof N Rezaei PhD); Department of Infectious Diseases, University of 
Copenhagen, Copenhagen, Denmark (O Rezahosseini MD); Department 
of Public Health and Informatics, Jahangirnagar University, Dhaka, 
Bangladesh (R K Ripon MSPH); Nursing Department, Ireland Hospital, 
Abbeyleix, Ireland (V Rodrigues MSc); Department of Lifestyle Research 
and Public Health, NA Semashko National Research Institute of Public 
Health, Moscow, Russia (D O Roshchin PhD); Department of Internal 
Medicine, University of Botswana, Gaborone, Botswana 
(G M Rwegerera MD); Department of Research and Development, 
Islamabad Diagnostic Centre Pakistan, Islamabad, Pakistan 
(U Saeed PhD); Biological Production Division, National Institute of 
Health, Islamabad, Pakistan (U Saeed PhD); Department of Psychiatry, 
All India Institute of Medical Sciences, New Delhi, India 
Articles
e648 www.thelancet.com/hiv   Vol 8   October 2021
(Prof R Sagar MD); Health Systems and Population Studies Division, 
International Centre for Diarrhoeal Disease Research, Bangladesh, 
Dhaka, Bangladesh (K Saif-Ur-Rahman MPH); Department of Public 
Health and Health Systems, Nagoya University, Nagoya, Japan 
(K Saif-Ur-Rahman MPH); Public Health and Community Medicine 
Department, Cairo University, Giza, Egypt (M R Salem MD); Emergency 
Department, Brown University, Providence, RI, USA (M Samaei MD); 
Department of Entomology, Ain Shams University, Cairo, Egypt 
(A M Samy PhD); Department of Community Medicine, Mahatma 
Gandhi Memorial Medical College, Indore, India (S Saroshe MD); 
Faculty of Health and Social Sciences, Bournemouth University, 
Bournemouth, UK (B Sathian PhD); UGC Centre of Advanced Study in 
Psychology, Utkal University, Bhubaneswar, India (M Satpathy PhD); 
Udyam-Global Association for Sustainable Development, Bhubaneswar, 
India (M Satpathy PhD); Department of Public Health Sciences, 
University of North Carolina at Charlotte, Charlotte, NC, USA 
(M Sawhney PhD); The George Institute for Global Health, Sydney, 
NSW, Australia (Prof A E Schutte PhD); National Heart, Lung, and Blood 
Institute, National Institute of Health, Rockville, MD, USA 
(A Seylani BS); Independent Consultant, Karachi, Pakistan 
(M A Shaikh MD); School of Public Health, Dilla University, Dilla, 
Ethiopia (M F Shaka MPH); Research Institute of Pharmaceutical 
Sciences, University of Karachi, Karachi, Pakistan (H Shamshad PhD); 
Faculty of Caring Science, Work Life, and Social Welfare, University of 
Borås, Borås, Sweden (M Shamsizadeh MSc); Department of 
Community Medicine, BLDE University, Vijayapur, India 
(M Shannawaz PhD); College of Medicine, Yonsei University, Seoul, 
South Korea (Prof J Shin MD); Public Health Dentistry Department, 
Krishna Institute of Medical Sciences Deemed to be University, Karad, 
India (Prof K M Shivakumar PhD); School of Medicine, University of 
Alabama at Birmingham, Birmingham, AL, USA (Prof J A Singh MD); 
Medicine Service, US Department of Veterans Affairs, Birmingham, AL, 
USA (Prof J A Singh MD); Department No 16 (V Y Skryabin MD), 
Laboratory of Genetics and Genomics (Prof M S Zastrozhin PhD), 
Moscow Research and Practical Centre on Addictions, Moscow, Russia; 
Therapeutic Department, Balashiha Central Hospital, Balashikha, Russia 
(A A Skryabina MD); Department of Medicine, University of Calgary, 
Calgary, AB, Canada (R Somayaji MD); Institute for Leadership and 
Health Management, Sechenov First Moscow State Medical University, 
Moscow, Russia (S Soshnikov PhD); International Vaccine Institute, 
Seoul, South Korea (B T Tadesse MD); HIV Health Promotion Division, 
HIV/AIDS Prevention Research Network, Kumba, Cameroon 
(E E Tarkang PhD); University Institute Egas Moniz, Monte da Caparica, 
Portugal (Prof N Taveira PhD); Research Institute for Medicines, 
University of Lisbon, Lisbon, Portugal (Prof N Taveira PhD); Department 
of Public Health, Madda Walabu University, Bale Robe, Ethiopia 
(Y Tekalegn MPH); Department of Pathology and Legal Medicine, 
University of São Paulo, Ribeirão Preto, Brazil (M R Tovani-Palone PhD); 
Modestum LTD, London, UK (M R Tovani-Palone PhD); Clinical 
Epidemiology and Public Health Research Unit, Burlo Garofolo Institute 
for Maternal and Child Health, Trieste, Italy (E Traini MSc); Department 
of Health Economics, Hanoi Medical University, Hanoi, Vietnam 
(B X Tran PhD); Department of Psychiatry, Massachusetts General 
Hospital, Boston, MA, USA (A C Tsai MD); Mbarara University of 
Science and Technology, Mbarara, Uganda (A C Tsai MD); Department 
of Epidemiology and Biostatistics, Haramaya University, Haramaya, 
Ethiopia (B S Tusa MPH); Department of Community Medicine, 
Alex Ekwueme Federal University Teaching Hospital Abakaliki, 
Abakaliki, Nigeria (C D Umeokonkwo MPH); Clinical Cancer Research 
Centre, Milad General Hospital, Tehran, Iran 
(S Valadan Tahbaz PhD, S Yahyazadeh Jabbari MD); Department of 
Microbiology, Islamic Azad University, Tehran, Iran 
(S Valadan Tahbaz PhD); Clinical Research Department, IRCCS 
Fondazione Don Carlo Gnocchi, Milan, Italy (J H Villafañe PhD); 
Laboratory of Public Health Indicators Analysis and Health 
Digitalization, Moscow Institute of Physics and Technology, 
Dolgoprudny, Russia (S K Vladimirov PhD); Faculty of Information 
Technology, Ho Chi Minh City University of Technology, Ho Chi Minh 
City, Vietnam (B Vo PhD); Centre of Excellence in Behavioral Medicine, 
Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam (G T Vu BA); 
Cultures, Societies and Global Studies, and Integrated Initiative for 
Global Health, Northeastern University, Boston, MA, USA 
(R G Wamai PhD); School of Health and Sport Sciences, University of 
Brighton, Eastbourne, UK (G Wang PhD); Competence Centre of 
Mortality-Follow-Up of the German National Cohort, Federal Institute 
for Population Research, Wiesbaden, Germany (R Westerman DSc); 
Institute of Health and Society, University of Oslo, Oslo, Norway 
(Prof A S Winkler PhD); Department of Neurology, Technical University 
of Munich, Munich, Germany (Prof A S Winkler PhD); Research and 
Development Division, The George Institute for Global Health, 
New Delhi, India (L Yadav PhD); Saw Swee Hock School of Public 
Health, National University of Singapore, Singapore (S Yi PhD); Khana 
Centre for Population Health Research, KHANA, Phnom Penh, 
Cambodia (S Yi PhD); Department of Health Management, Süleyman 
Demirel Üniversitesi, Isparta, Turkey (V Yiğit PhD); Department of 
Neuropsychopharmacology, National Centre of Neurology and 
Psychiatry, Kodaira, Japan (N Yonemoto MPH); Department of Public 
Health, Juntendo University, Tokyo, Japan (N Yonemoto MPH); 
Department of Clinical Pharmacy and Outcomes Sciences, University of 
South Carolina, Columbia, SC, USA (I Yunusa PhD); Addictology 
Department (Prof M S Zastrozhin PhD), Paediatrics Department 
(A Zastrozhina PhD), Russian Medical Academy of Continuous 
Professional Education, Moscow, Russia; Center for Health Policy and 
Center for Primary Care and Outcomes Research 
(Prof J A Salomon PhD), Stanford University, Stanford, CA, USA.
Declaration of interests
S Afzal reports an unpaid leadership role as General Secretary for the 
Pakistan Society of Community Medicine and Public Health, working 
for prevention and advocacy of AIDS in families of HIV patients by 
providing advocacy and counseling services to the families, children, 
and partners of patients with AIDS and screening them for HIV in 
Pakistan, outside the submitted work. T Bärnighausen reports research 
grants from the European Union (Horizon 2020 and EIT Health), 
German Research Foundation (also known as DFG), US National 
Institutes of Health (NIH), German Ministry of Education and Research, 
Alexander von Humboldt Foundation, Else-Kröner-Fresenius-
Foundation, the Wellcome Trust, the Bill & Melinda Gates Foundation, 
KfW, UNAIDS, and WHO; consulting fees for KfW on the OSCAR 
initiative in Vietnam; and participation on a Data Safety Monitoring 
Board or Advisory Board through the NIH-funded study Healthy 
Options (Principle Investigators Smith Fawzi, Kaaya), Chair, Data Safety 
and Monitoring Board, German National Committee on the Future of 
Public Health Research and Education, Chair of the scientific advisory 
board to the EDCTP Evaluation, Member of the UNAIDS Evaluation 
Expert Advisory Committee, National Institutes of Health Study Section 
Member on Population and Public Health Approaches to HIV/AIDS, US 
National Academies of Sciences, Engineering, and Medicine’s 
Committee for the Evaluation of Human Resources for Health in the 
Republic of Rwanda under the President’s Emergency Plan for AIDS 
Relief (also known as PEPFAR), University of Pennsylvania Population 
Aging Research Center External Advisory Board Member; and a 
leadership or fiduciary role in other board, society, committee, or 
advocacy group, paid or unpaid as Co-Chair of the Global Health Hub 
Germany (which was initiated by the German Ministry of Health), all 
outside the submitted work. J Eaton reports institutional support for the 
manuscript from the Gates Foundation, UNAIDS, and National 
Institutes of Health; grants or contracts from WHO, Gates foundation, 
and UNAIDS; consulting fees from WHO; and support for attending 
meetings or travel from WHO and UNAIDS, all outside the submitted 
work. I Filip reports financial support from Avicenna Medical and 
Clinical Research Institute, outside the submitted work. I Iyamu reports 
support for attending FHI 360 HIV prevention, care, and treatment 
training events in Nigeria, outside the submitted work. K Krishan 
reports non-financial support from UGC Centre of Advanced Study, CAS 
II, Department of Anthropology, Panjab University, Chandigarh, India, 
outside the submitted work. K LeGrand reports support for the present 
manuscript through payment to the institution (Institute for Health 
Metrics and Evaluation) from the Gates Foundation. M Postma reports a 
leadership or fiduciary role in other board, society, committee, or 
advocacy group, unpaid as member of UK’s JCVI. O Rezahosseini 
reports grants or contracts from the Research Foundation of 
Articles
www.thelancet.com/hiv   Vol 8   October 2021 e649
Rigshospitalet and the A P Møller Fonden; and support for attending 
meetings or travel from EACS 2019 Basel, all outside the submitted 
work. J Salomon reports support for the present manuscript through a 
research grant paid to the institution (Institute for Health Metrics and 
Evaluation) from the Gates Foundation. J Singh reports consulting fees 
from Crealta/Horizon, Medisys, Fidia, Two labs, Adept Field Solutions, 
Clinical Care Options, Clearview Health-Care Partners, Putnam 
Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, 
UBM LLC, Trio Health, Medscape, WebMD, and Practice Point 
Communications, the NIH, and the American College of Rheumatology; 
payment or honoraria for lectures, presentations, speakers bureaus, 
manuscript writing, or educational events from Simply Speaking; 
support for attending meetings or travel from OMERACT, an 
international organisation that develops measures for clinical trials and 
receives arm’s-length funding from 12 pharmaceutical companies, when 
traveling biannually to OMERACT meetings; participation on a Data 
Safety Monitoring Board or Advisory Board as a member of the FDA 
Arthritis Advisory Committee; a leadership or fiduciary role in other 
board, society, committee, or advocacy group, paid or unpaid, with 
OMERACT as a member of the steering committee, with the Veterans 
Affairs Rheumatology Field Advisory Committee as a member, and with 
the UAB Cochrane Musculoskeletal Group Satellite Center on Network 
Meta-analysis as a director and editor; and stock or stock options in 
TPT Global Tech, Vaxart pharmaceuticals, Charlotte’s Web Holdings, 
and previously owned stock options in Amarin, Viking, and Moderna 
pharmaceuticals, all outside the submitted work. D Stein reports 
personal fees from Lundbeck, Takeda, Johnson & Johnson and Servier, 
all outside the submitted work. A Tsai reports stipend for work as Editor-
in-Chief of Social Science and Medicine, Mental Health from Elsevier. 
All other authors declare no competing interests. 
Data sharing
To download the data used in these analyses, please visit the Global 
Health Data Exchange GBD 2019 data-input sources tool at http://ghdx.
healthdata.org/gbd-2019/data-input-sources.
Acknowledgments
L Abu-Raddad acknowledges the support of Qatar National Research 
Fund (NPRP 9-040-3-008) who provided the main funding for generating 
the data provided to the GBD-IHME effort. T Bärnighausen was 
supported by the Alexander von Humboldt Foundation through the 
Alexander von Humboldt Professor award, funded by the German 
Federal Ministry of Education and Research. S Bazargan-Hejazi was 
partly supported by the National Institute of Health (NIH) National 
Center for Advancing Translational Science UCLA CTSI (grant 
number UL1TR001881). L Degenhardt is supported by an NHMRC 
Senior Principal Research Fellowship (1135991) and a US NIH National 
Institute on Drug Abuse (NIDA) grant (R01DA1104470). NDARC, UNSW 
Sydney, is supported by funding from the Australian Government 
Department of Health under the Drug and Alcohol Programme. J Eaton 
was supported by the Bill & Melinda Gates Foundation (OPP1190661), 
UNAIDS, the National Institute of Allergy and Infectious Disease of the 
NIH under award numbers R01AI136664, and the MRC Centre for 
Global Infectious Disease Analysis (reference MR/R015600/1), jointly 
funded by the UK Medical Research Council (MRC) and the UK Foreign, 
Commonwealth, and Development Office (FCDO), under the MRC/
FCDO Concordat agreement and is also part of the EDCTP2 programme 
supported by the European Union. V B Gupta acknowledges funding 
support from National Health and Medical Research Council (NHMRC), 
Australia. V K Gupta acknowledges support from NHMRC, 
Australia. S Haque is grateful to the DSR, Jazan University, Saudi Arabia 
for providing the access of the Saudi Digital Library for this study. 
P Hoogar would like to acknowledge the Centre for Bio Cultural Studies 
Directorate of Research, Manipal Academy of Higher Education, 
Manipal-Karnataka, India. Y J Kim’s portion of this work was supported 
by the Research Management Centre, Xiamen University Malaysia 
(Np:XMUMRF-C6/ITCM/0004). S L Koulmane Laxminarayana 
acknolwedges institutional support by Manipal Academy of Higher 
Education. K Krishan is supported by the UGC Centre of Advanced 
Study (phase 2), awarded to the Department of Anthropology, Panjab 
University, Chandigarh, India. M Kumar acknowledges grant FIC/NIH 
K43 TW010716-04. I Landires is member of the Sistema Nacional de 
Investigación, supported by the Secretaría Nacional de Ciencia, 
Tecnología e Innovación, Panama. J Lazarus acknowledges support to 
ISGlobal from the Spanish Ministry of Science, Innovation, and 
Universities through the Centro de Excelencia Severo Ochoa 2019–23 
programme (CEX2018-000806-S), and from the Government of 
Catalonia, Spain, through the CERCA programme. P Mahasha 
acknowledges grants, innovation, and product development from the 
South African Medical Research Council. P Meylahk’s portion of this 
research was supported by the Russian Science Foundation (under grant 
project number 20-18-00307; the health of nation: the multidimensional 
analysis of health, health inequality, and health-related quality of life). 
M Molokhia is supported by the National Institute for Health Research 
Biomedical Research Centre at Guy’s and St Thomas’ National Health 
Service Foundation Trust and King’s College London. J Nachega is an 
infectious disease internist and epidemiologist and Principal 
Investigator of NIH/Fogarty International Center (grant numbers 
1R25TW011217-01, 1R21TW011706-01, and 1D43TW010937-01A1). A Samy 
acknowledges support from a fellowship of the Egyptian Fulbright 
Mission programme. A Shetty acknowledges the support given by 
Kasturba Medical College Mangalore, Manipal Academy of Higher 
Education, Manipal. N Taveira’s work is partially funded by Fundação 
para a Ciência e Tecnologia, Portugal, and Aga Khan Development 
Network, Portugal Collaborative Research Network in Portuguese 
speaking countries in Africa (project 332821690), and by the LIFE project 
(RIA2016MC-1615), and European and Developing Countries Clinical 
Trials Partnership. G Tessema was funded by the Australian National 
Health and Medical Research Council Investigator (grant number 
1195716). B Unnikrishnan acknowledges Kasturba Medical College, 
Mangalore, Manipal Academy of Higher Education, Manipal. A Zumla 
acknowledges support from the European and Developing Countries 
Clinical Trials Partnership programme, Horizon 2020, and the European 
Union’s Framework Programme for Research and Innovation (grants 
PANDORA-ID-NET, TESA-2, and CANTAM-2).
References
1 WHO. MDG 6: combat HIV/AIDS, malaria and other diseases. 
https://www.who.int/topics/millennium_development_goals/
diseases/en/ (accessed July 9, 2020).
2 WHO. Global health sector response to HIV, 2000–2015: focus on 
innovations in Africa: progress report. Geneva: World Health 
Organization, 2015.
3 Nursing and the United Nations 2030 Agenda for Sustainable 
Development. Transforming our world: the 2030 agenda for 
sustainable development. In: Rosa W, ed. A new era in global 
health. New York, NY: Springer Publishing Company, 2017.
4 Hogan AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of 
the COVID-19 pandemic on HIV, tuberculosis, and malaria in 
low-income and middle-income countries: a modelling study. 
Lancet Glob Health 2020; 8: e1132–41.
5 Tamuzi JL, Ayele BT, Shumba CS, et al. Implications of COVID-19 
in high burden countries for HIV/TB: a systematic review of 
evidence. BMC Infect Dis 2020; 20: 744.
6 UNAIDS. 90-90-90: treatment for all. https://www.unaids.org/en/
resources/909090 (accessed Jan 8, 2021).
7 Haber NA, Lesko CR, Fox MP, et al. Limitations of the UNAIDS 
90-90-90 metrics: a simulation-based comparison of cross-sectional 
and longitudinal metrics for the HIV care continuum. AIDS 2020; 
34: 1047–55.
8 Ghys PD, Williams BG, Over M, Hallett TB, Godfrey-Faussett P. 
Epidemiological metrics and benchmarks for a transition in the 
HIV epidemic. PLoS Med 2018; 15: e1002678.
9 Magadi MA. Understanding the gender disparity in HIV infection 
across countries in sub-Saharan Africa: evidence from the 
Demographic and Health Surveys. Sociol Health Illn 2011; 33: 522–39.
10 Okano JT, Blower S. Sex-specific maps of HIV epidemics in 
sub-Saharan Africa. Lancet Infect Dis 2016; 16: 1320–22.
11 UNAIDS. Women and HIV: a spotlight on adolescent girls and 
young women. 2019. https://www.unaids.org/sites/default/files/
media_asset/2019_women-and-hiv_en.pdf (accessed 
May 13, 2021).
12 Pendse R, Gupta S, Yu D, Sarkar S. HIV/AIDS in the south-east 
Asia region: progress and challenges. J Virus Erad 2016; 
2 (suppl 4): 1–6.
Articles
e650 www.thelancet.com/hiv   Vol 8   October 2021
13 Gökengin D, Oprea C, Uysal S, Begovac J. The growing HIV epidemic 
in Central Europe: a neglected issue? J Virus Erad 2016; 2: 156–61.
14 Mumtaz GR, Riedner G, Abu-Raddad LJ. The emerging face of the 
HIV epidemic in the Middle East and North Africa. 
Curr Opin HIV AIDS 2014; 9: 183–91.
15 Frank TD, Carter A, Jahagirdar D, et al. Global, regional, 
and national incidence, prevalence, and mortality of HIV, 1980-2017, 
and forecasts to 2030, for 195 countries and territories: a systematic 
analysis for the Global Burden of Diseases, Injuries, and Risk 
Factors Study 2017. Lancet HIV 2019; 6: e831–59.
16 Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and 
injuries in 204 countries and territories, 1990-2019: a systematic 
analysis for the Global Burden of Disease Study 2019. Lancet 2020; 
396: 1204–22.
17 Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk 
factors in 204 countries and territories, 1990–2019: a systematic 
analysis for the Global Burden of Disease Study 2019. Lancet 2020; 
396: 1223–49.
18 Wang H, Abbas KM, Abbasifard M, et al. Global age-sex-specific 
fertility, mortality, healthy life expectancy (HALE), and population 
estimates in 204 countries and territories, 1950–019: a comprehensive 
demographic analysis for the Global Burden of Disease Study 2019. 
Lancet 2020; 396: 1160–203.
19 Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and 
transparent health estimates reporting: the GATHER statement. 
Lancet 2016; 388: e19–23.
20 Eaton JW, Brown T, Puckett R, et al. The estimation and projection 
package age-sex model and the r-hybrid model: new tools for 
estimating HIV incidence trends in sub-Saharan Africa. AIDS 2019; 
33 (suppl 3): S235–44.
21 Mahy M, Penazzato M, Ciaranello A, et al. Improving estimates of 
children living with HIV from the Spectrum AIDS Impact Model. 
AIDS 2017; 31 (suppl 1): S13–22.
22 Brown T, Bao L, Eaton JW, et al. Improvements in prevalence trend 
fitting and incidence estimation in EPP 2013. AIDS 2014; 
28 (suppl 4): S415–25.
23 Righi MK, Orchowski LM, Kuo C. Integrated intimate partner 
violence and HIV interventions among adolescents in sub-Saharan 
Africa: a systematic review. Trauma Violence Abuse 2020; 21: 643–59.
24 Griesbeck M, Scully E, Altfeld M. Sex and gender differences in 
HIV-1 infection. Clin Sci 2016; 130: 1435–51.
25 Dieleman JL, Haakenstad A, Micah A, et al. Spending on health and 
HIV/AIDS: domestic health spending and development assistance 
in 188 countries, 1995–2015. Lancet 2018; 391: 1799–829.
26 Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. 
High coverage of ART associated with decline in risk of HIV 
acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 
339: 966–71.
27 Yu D, Souteyrand Y, Banda MA, Kaufman J, Perriëns JH. 
Investment in HIV/AIDS programs: does it help strengthen health 
systems in developing countries? Glob Health 2008; 4: 8.
28 Halperin DT, Mugurungi O, Hallett TB, et al. A surprising 
prevention success: why did the HIV epidemic decline in 
Zimbabwe? PLoS Med 2011; 8: e1000414.
29 Green EC, Halperin DT, Nantulya V, Hogle JA. Uganda’s HIV 
prevention success: the role of sexual behavior change and the 
national response. AIDS Behav 2006; 10: 335–46.
30 Dwyer-Lindgren L, Cork MA, Sligar A, et al. Mapping HIV 
prevalence in sub-Saharan Africa between 2000 and 2017. Nature 
2019; 570: 189–93. 
31 Local Burden of Disease HIV Collaborators. Subnational mapping 
of HIV incidence and mortality among adults ages 15 to 49 in 
sub-Saharan Africa, 2000–18. Lancet HIV; 8: e363–75.
32 Holmes CB, Sikazwe I, Sikombe K, et al. Estimated mortality on HIV 
treatment among active patients and patients lost to follow-up in 
4 provinces of Zambia: findings from a multistage sampling-based 
survey. PLoS Med 2018; 15: e1002489.
33 LaMonaca K, Dumchev K, Dvoriak S, Azbel L, Morozova O, 
Altice FL. HIV, drug injection, and harm reduction trends in 
eastern Europe and central Asia: implications for international and 
domestic policy. Curr Psychiatry Rep 2019; 21: 47.
34 Kharsany ABM, Karim QA. HIV infection and AIDS in sub-Saharan 
Africa: current status, challenges and opportunities. Open AIDS J 
2016; 10: 34–48.
35 Ortblad KF, Baeten JM, Cherutich P, Wamicwe JN, Wasserheit JN. 
The arc of HIV epidemics in sub-Saharan Africa: new challenges 
with concentrating epidemics in the era of 90-90-90. 
Curr Opin HIV AIDS 2019; 14: 354–65.
36 Sullivan PS, Satcher Johnson A, Pembleton ES, et al. Epidemiology 
of HIV in the USA: epidemic burden, inequities, contexts, and 
responses. Lancet 2021; 397: 1095–106.
37 Stuikyte R, Barbosa I, Kazatchkine M. Getting to grips with the HIV 
epidemic in Russia. Curr Opin HIV AIDS 2019; 14: 381–86.
38 De Boni R, Veloso VG, Grinsztejn B. Epidemiology of HIV in 
Latin America and the Caribbean. Curr Opin HIV AIDS 
2014; 9: 192–98.
39 Holt M. Progress and challenges in ending HIV and AIDS in 
Australia. AIDS Behav 2017; 21: 331–34.
40 Annequin M, Villes V, Delabre RM, et al. Are PrEP services in 
France reaching all those exposed to HIV who want to take PrEP? 
MSM respondents who are eligible but not using PrEP (EMIS 2017). 
AIDS Care 2020; 32: 47–56.
41 Sullivan PS, Mena L, Elopre L, Siegler AJ. Implementation 
strategies to increase PrEP uptake in the South. Curr HIV/AIDS Rep 
2019; 16: 259–69.
42 Wirawan DN. Stigma and discrimination: barrier for ending AIDS 
by 2030 and achieving the 90-90-90 targets by 2020. PHPMA 2019; 
7: 1.
43 Nyblade L, Mingkwan P, Stockton MA. Stigma reduction: 
an essential ingredient to ending AIDS by 2030. Lancet HIV 2021; 
8: e106–13.
44 Ghose T, Swendeman DT, George SM. The role of brothels in 
reducing HIV risk in Sonagachi, India. Qual Health Res 2011; 
21: 587–600.
45 Siraprapasiri T, Ongwangdee S, Benjarattanaporn P, 
Peerapatanapokin W, Sharma M. The impact of Thailand’s public 
health response to the HIV epidemic 1984-2015: understanding the 
ingredients of success. J Virus Erad 2016; 2 (suppl 4): 7–14.
46 Thisyakorn U. Elimination of mother-to-child transmission of HIV: 
lessons learned from success in Thailand. Paediatr Int Child Health 
2017; 37: 99–108.
47 Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall 
and comorbidity-free life expectancy between insured adults with 
and without HIV infection, 2000–2016. JAMA Netw Open 2020; 
3: e207954.
48 Galvani AP, Pandey A, Fitzpatrick MC, Medlock J, Gray GE. 
Defining control of HIV epidemics. Lancet HIV 2018; 5: e667–70.
49 Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in 
life expectancy among treated HIV-positive individuals in the 
United States and Canada. PLoS One 2013; 8: e81355.
50 Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of 
HIV healthcare in the HAART era. AIDS 2010; 24: 2705–15.
51 PEPFAR. US President’s Emergency Plan for AIDS Relief. 
Strategy for accelerating HIV/AIDS epidemic control (2017–2020). 
https://www.state.gov/wp-content/uploads/2019/08/PEPFAR-
Strategy-for-Accelerating-HIVAIDS-Epidemic-Control-2017-2020.
pdf (accessed Feb 28, 2021).
52 Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and 
COVID-19: summary of the data and responses to date. 
Curr Opin HIV AIDS 2021; 16: 63–73.
53 Jiang H, Zhou Y, Tang W. Maintaining HIV care during the 
COVID-19 pandemic. Lancet HIV 2020; 7: e308–09.
54 Guo W, Weng HL, Bai H, et al. Quick community survey on the 
impact of COVID-19 outbreak for the healthcare of people living 
with HIV. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41: 662–66 
(in Chinese).
55 Lagat H, Sharma M, Kariithi E, et al. Impact of the COVID-19 
pandemic on HIV testing and assisted partner notification services, 
western Kenya. AIDS Behav 2020; 24: 3010–13.
56 UNAIDS. UNAIDS and China working together during the 
COVID-19 outbreak to ensure that people living with HIV continue 
to get treatment. https://www.unaids.org/en/resources/
presscentre/pressreleaseandstatementarchive/2020/
february/20200218_china_covid19 (accessed Jan 11, 2021).
57 Odhiambo F, Mulwa E, Ayieko J, et al. Implementation of HIV care 
in western Kenya during corona virus disease 2019 response. AIDS 
2020; 34: F1–2.
Articles
www.thelancet.com/hiv   Vol 8   October 2021 e651
58 Global Network of People living with HIV (GNP+), International 
Commnity of Women Living with HIV, Global Network of Young 
People Living with HIV. Living with HIV in the time of COVID-19: 
report from a survey of networks of people living with HIV. 2020. 
https://gnpplus.net/wp-content/uploads/2020/07/BeyondLIVING_
COVID-19_English.pdf (accessed March 3, 2021).
59 UNAIDS, Global HIV Prevention Coalition. Maintaining and 
prioritizing HIV prevention services in the time of COVID-19. 
2020. https://www.unaids.org/sites/default/files/media_asset/
maintaining-prioritizing-hiv-prevention-services-covid19_en.pdf 
(accessed March 3, 2021).
60 WHO. Coronavirus disease (COVID-19): HIV and antiretrovirals. 
Geneva: World Health Organization, 2020.
61 PEPFAR. US President’s Emergency Plan for AIDS Relief. PEPFAR 




62 HIV.gov. Global Statistics. Nov 25, 2020. https://www.hiv.gov/hiv-
basics/overview/data-and-trends/global-statistics (accessed 
Jan 11, 2021).
